<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">95887</article-id>
<article-id pub-id-type="doi">10.7554/eLife.95887</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95887.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Genetics and Genomics</subject>
</subj-group>
</article-categories><title-group>
<article-title>Heterozygous variants in <italic>PLCG1</italic> affect hearing, vision, cardiac, and immune function</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Ma</surname>
<given-names>Mengqi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zheng</surname>
<given-names>Yiming</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
<xref ref-type="author-notes" rid="n2">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deng</surname>
<given-names>Mingxi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Shenzhao</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pan</surname>
<given-names>Xueyang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luo</surname>
<given-names>Xi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Etoundi</surname>
<given-names>Michelle</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li-Kroeger</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Worley</surname>
<given-names>Kim C</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burrage</surname>
<given-names>Lindsay C</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blieden</surname>
<given-names>Lauren S</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Allworth</surname>
<given-names>Aimee</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="author-notes" rid="n3">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Wei-Liang</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="author-notes" rid="n4">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Merla</surname>
<given-names>Giuseppe</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mandriani</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Otten</surname>
<given-names>Catherine E</given-names>
</name>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blanc</surname>
<given-names>Pierre</given-names>
</name>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosenfeld</surname>
<given-names>Jill A</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dutta</surname>
<given-names>Debdeep</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n5">¶</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2172-8036</contrib-id>
<name>
<surname>Yamamoto</surname>
<given-names>Shinya</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wangler</surname>
<given-names>Michael F</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<collab>Undiagnosed Diseases Network</collab>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Glass</surname>
<given-names>Ian A</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a11">11</xref>
<xref ref-type="aff" rid="a12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Jingheng</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0633-0305</contrib-id>
<name>
<surname>Blue</surname>
<given-names>Elizabeth</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
<xref ref-type="aff" rid="a12">12</xref>
<xref ref-type="aff" rid="a13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prontera</surname>
<given-names>Paolo</given-names>
</name>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosain</surname>
<given-names>Jeremie</given-names>
</name>
<xref ref-type="aff" rid="a15">15</xref>
<xref ref-type="aff" rid="a16">16</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marlin</surname>
<given-names>Sandrine</given-names>
</name>
<xref ref-type="aff" rid="a17">17</xref>
<xref ref-type="aff" rid="a18">18</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lalani</surname>
<given-names>Seema R</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Bellen</surname>
<given-names>Hugo J</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<email>hbellen@bcm.edu</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Molecular and Human Genetics, Baylor College of Medicine</institution></institution-wrap>, <city>Houston</city>, <country country="US">United States</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05cz92x43</institution-id><institution>Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital</institution></institution-wrap>, <city>Houston</city>, <country country="US">United States</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Neurology, Baylor College of Medicine</institution></institution-wrap>, <city>Houston</city>, <country country="US">United States</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>The Cullen Eye Institute, Department of Ophthalmology, Baylor College of Medicine</institution></institution-wrap>, <city>Houston</city>, <country country="US">United States</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine</institution></institution-wrap>, <city>Seattle</city>, <country country="US">United States</country></aff>
<aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00md77g41</institution-id><institution>Laboratory of Regulatory &amp; Functional Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza</institution></institution-wrap>, <city>San Giovanni Rotondo</city>, <country country="IT">Italy</country></aff>
<aff id="a7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05290cv24</institution-id><institution>Department of Molecular Medicine &amp; Medical Biotechnology, University of Naples Federico II</institution></institution-wrap>, <city>Naples</city>, <country country="IT">Italy</country></aff>
<aff id="a8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/027ynra39</institution-id><institution>Department of Interdisciplinary Medicine, University of Bari &quot;Aldo Moro&quot;</institution></institution-wrap>, <city>Bari</city>, <country country="IT">Italy</country></aff>
<aff id="a9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01njes783</institution-id><institution>Department of Neurology, University of Washington and Seattle Children’s Hospital</institution></institution-wrap>, <city>Seattle</city>, <country country="US">United States</country></aff>
<aff id="a10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00pg5jh14</institution-id><institution>SeqOIA Genomics Platform, Assistance Publique–Hôpitaux de Paris (AP-HP)</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff>
<aff id="a11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Division of Genetic Medicine, Department of Pediatrics, University of Washington School of Medicine</institution></institution-wrap>, <city>Seattle</city>, <country country="US">United States</country></aff>
<aff id="a12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03jxvbk42</institution-id><institution>Brotman Baty Institute</institution></institution-wrap>, <city>Seattle</city>, <country country="US">United States</country></aff>
<aff id="a13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00cvxb145</institution-id><institution>Institute for Public Health Genetics, University of Washington</institution></institution-wrap>, <city>Seattle</city>, <country country="US">United States</country></aff>
<aff id="a14"><label>14</label><institution>Medical Genetics and Rare Diseases Unit, Hospital of Perugia</institution>, <city>Perugia</city>, <country country="IT">Italy</country></aff>
<aff id="a15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05tr67282</institution-id><institution>Laboratory of Human Genetics of Infectious Diseases, Imagine Institute, Necker Hospital for Sick Children</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff>
<aff id="a16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05tr67282</institution-id><institution>Center for the Study of Immune Deficiencies, Necker-Enfants Malades Hospital, AP-HP Centre, University of Paris</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff>
<aff id="a17"><label>17</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rq3rb55</institution-id><institution>Genetics of Rare Ophthalmological, Auditory and Mitochondrial Disorders, Inserm UMR_S1163, Imagine Institute</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff>
<aff id="a18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05tr67282</institution-id><institution>Reference Center for Genetic Deafness, Department of Genomic Medicine for Rare Diseases, Necker-Enfants Malades Hospital, AP-HP Centre, University of Paris</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Nahmad</surname>
<given-names>Marcos</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Center for Research and Advanced Studies of the National Polytechnic Institute</institution>
</institution-wrap>
<city>Mexico City</city>
<country country="MX">Mexico</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Desplan</surname>
<given-names>Claude</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>New York University</institution>
</institution-wrap>
<city>New York</city>
<country country="US">United States</country>
</aff>
</contrib>
</contrib-group>
<author-notes><fn id="n1" fn-type="equal"><label>*</label><p>These authors contributed equally;</p></fn>
<fn id="n2" fn-type="present-address"><label>†</label><p>Present address: State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China</p></fn>
<fn id="n3" fn-type="present-address"><label>‡</label><p>Present address: Invitae Corporation, San Francisco, United States</p></fn>
<fn id="n4" fn-type="present-address"><label>§</label><p>Present address: Children’s National Medical Center and George Washington University, Washington DC, United States</p></fn>
<fn id="n5" fn-type="present-address"><label>¶</label><p>Present address: Department of Biological Sciences &amp; Bioengineering, and Mehta Family Centre for Engineering in Medicine, Indian Institute of Technology Kanpur, Kanpur, India</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing completed at Baylor Genetics Laboratories.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-04-19">
<day>19</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-07-23">
<day>23</day>
<month>07</month>
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP95887</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-02-05">
<day>05</day>
<month>02</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-01-09">
<day>09</day>
<month>01</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.08.23300523"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-04-19">
<day>19</day>
<month>04</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95887.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.95887.1.sa3">eLife assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.95887.1.sa2">Reviewer #1 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.95887.1.sa1">Reviewer #2 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.95887.1.sa0">Reviewer #3 (Public Review):</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Ma et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Ma et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-95887-v2.pdf"/>
<abstract>
<title>Abstract</title><p>Phospholipase C isozymes (PLCs) hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) into inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and diacylglycerol (DAG), important signaling molecules involved in many cellular processes including Ca<sup>2+</sup> release from the endoplasmic reticulum (ER). <italic>PLCG1</italic> encodes the PLCγ1 isozyme that is broadly expressed. Hyperactive somatic mutations of <italic>PLCG1</italic> are observed in multiple cancers, but only one germline variant has been reported. Here we describe seven individuals with heterozygous missense variants in <italic>PLCG1</italic> [p.(Asp1019Gly), p.(His380Arg), p.(Asp1165Gly), and p.(Leu597Phe)] who present with hearing impairment (5/7), ocular pathology (4/7), cardiac septal defects (3/6), and various immunological issues (5/7). To model these variants <italic>in vivo</italic>, we generated the analogous variants in the <italic>Drosophila</italic> ortholog, <italic>small wing</italic> (<italic>sl</italic>). We created a null allele <italic>sl<sup>T2A</sup></italic> and assessed its expression pattern. <italic>sl</italic> is broadly expressed, including wing discs, eye discs, and a subset of neurons and glia. <italic>sl<sup>T2A</sup></italic>mutant flies exhibit wing size reductions, ectopic wing veins, and supernumerary photoreceptors. We document that mutant flies also exhibit a reduced lifespan and age-dependent locomotor defects. Expressing wild-type <italic>sl</italic> in <italic>sl<sup>T2A</sup></italic> mutant flies rescues the loss-of-function phenotypes, whereas the variants increase lethality. Ectopic expression of an established hyperactive <italic>PLCG1</italic> variant, p.(Asp1165His) in the wing pouch causes elevated Ca<sup>2+</sup> activity and severe wing phenotypes. These phenotypes are also observed when the p.(Asp1019Gly) or p.(Asp1165Gly) variants are overexpressed in the wing pouch, arguing that these are gain-of-function variants. However, the wing phenotypes associated with p.(His380Arg) or p.(Leu597Phe) overexpression are either mild or only partially penetrant. Our data suggest that the heterozygous missense variants reported here affect protein function differentially and contribute to the clinical features observed in the affected individuals.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Phospholipase C</kwd>
<kwd><italic>Drosophila</italic></kwd>
<kwd>phenotypic heterogeneity</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>The ethics committee of the National Human Genome Research Institute gave ethical approval for this work.
The ethics committee of the Santa Maria della Misericordia Hospital gave ethical approval for this work.</p><p>I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.</p><p>Yes</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>New cases and new assays have been included.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The inositol lipid-specific phospholipase C (PLC) isozymes are key signaling proteins that play critical roles in transducing signals from hormones, growth factors, neurotransmitters, and many extracellular stimuli (<xref ref-type="bibr" rid="c8">Berridge and Irvine 1984</xref>; <xref ref-type="bibr" rid="c18">Exton 1996</xref>; <xref ref-type="bibr" rid="c4">Balla 2013</xref>). The PLCs selectively hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) into inositol 1,4,5-trisphosphate (IP<sub>3</sub>) and diacylglycerol (DAG) (<xref ref-type="bibr" rid="c49">Nishizuka 1984</xref>; <xref ref-type="bibr" rid="c45">Majerus et al. 1986</xref>). PIP2 functions as a membrane anchor for numerous proteins and affects membrane dynamics and ion transport (<xref ref-type="bibr" rid="c26">Hilgemann et al. 2001</xref>; <xref ref-type="bibr" rid="c25">Hilgemann 2007</xref>; <xref ref-type="bibr" rid="c66">Suh and Hille 2008</xref>). The two products, IP<sub>3</sub> and DAG, are important intracellular second messengers involved in Ca<sup>2+</sup> signaling regulation and protein kinase C signaling activation, respectively (<xref ref-type="bibr" rid="c50">Nishizuka 1992</xref>; <xref ref-type="bibr" rid="c7">Berridge 1993</xref>). Hence, PLC orchestrates diverse cellular processes and behaviors, including cell growth, differentiation, migration, and cell death (<xref ref-type="bibr" rid="c77">Yang et al. 2012</xref>; <xref ref-type="bibr" rid="c11">Cocco et al. 2015</xref>; <xref ref-type="bibr" rid="c20">Gomes et al. 2021</xref>; <xref ref-type="bibr" rid="c2">Asano et al. 2022</xref>). There are at least thirteen PLC isozymes grouped in 6 classes (β, δ, ε, γ, η, ζ) in mammals with similar enzymatic function, but each PLC has its own spectrum of activators, expression pattern, and subcellular distribution (<xref ref-type="bibr" rid="c67">Suh et al. 2008</xref>; <xref ref-type="bibr" rid="c32">Kadamur and Ross 2013</xref>; <xref ref-type="bibr" rid="c34">Katan and Cockcroft 2020</xref>).</p>
<p><italic>PLCG1</italic> [MIM: 172420] encodes the PLCγ1 isozyme. PLCγ1 can be directly activated by receptor tyrosine kinases (RTKs) as well as cytosolic receptors coupled to tyrosine kinases (<xref ref-type="bibr" rid="c22">Gresset et al. 2012</xref>). Upon tyrosine phosphorylation, PLCγ1 undergoes conformational changes that release its autoinhibition upon which it associates with the plasma membrane to bind and hydrolyze its substrates (<xref ref-type="bibr" rid="c21">Gresset et al. 2010</xref>; <xref ref-type="bibr" rid="c24">Hajicek et al. 2019</xref>; <xref ref-type="bibr" rid="c52">Nosbisch et al. 2022</xref>). There is a second PLCγ isozyme, PLCγ2, encoded by <italic>PLCG2</italic> [MIM: 600220]. Although these two isozymes have similar protein structure and activation mechanism, they are differentially expressed and regulated, and play non-redundant roles (<xref ref-type="bibr" rid="c27">Homma et al. 1989</xref>; <xref ref-type="bibr" rid="c58">Regunathan et al. 2006</xref>). <italic>PLCG2</italic> is mostly expressed in cells of the hematopoietic system and mainly functions in immune response, causing human diseases associated with immune disorders (<xref ref-type="bibr" rid="c78">Yu et al. 2005</xref>; <xref ref-type="bibr" rid="c53">Ombrello et al. 2012</xref>; <xref ref-type="bibr" rid="c79">Zhou et al. 2012</xref>; <xref ref-type="bibr" rid="c48">Neves et al. 2018</xref>; <xref ref-type="bibr" rid="c5">Baysac et al. 2024</xref>). However, <italic>PLCG1</italic> is ubiquitously expressed and is enriched in the central nervous system (CNS) (<xref ref-type="bibr" rid="c12">Consortium 2015</xref>). <italic>Plcg1</italic> is essential in mice, and a null allele causes embryonic lethality with developmental defects in the vascular, neuronal, and immune system (<xref ref-type="bibr" rid="c31">Ji et al. 1997</xref>; <xref ref-type="bibr" rid="c40">Liao et al. 2002</xref>). <italic>PLCG1</italic> has emerged as a possible driver for cell proliferation, and increased expression levels of <italic>PLCG1</italic> have been observed in breast cancer, colon cancer, and squamous cell carcinoma (<xref ref-type="bibr" rid="c1">Arteaga et al. 1991</xref>; <xref ref-type="bibr" rid="c51">Noh et al. 1994</xref>; <xref ref-type="bibr" rid="c55">Park et al. 1994</xref>; <xref ref-type="bibr" rid="c76">Xie et al. 2010</xref>). Moreover, hyperactive somatic mutations of <italic>PLCG1</italic> have been observed in angiosarcomas and T cell leukemia/lymphomas (<xref ref-type="bibr" rid="c6">Behjati et al. 2014</xref>; <xref ref-type="bibr" rid="c36">Kunze et al. 2014</xref>; <xref ref-type="bibr" rid="c72">Vaque et al. 2014</xref>; <xref ref-type="bibr" rid="c35">Kataoka et al. 2015</xref>). However, the genotype-phenotype association of germline <italic>PLCG1</italic> variants has yet to be explored.</p>
<p>Here, we reported seven individuals carrying heterozygous variants in <italic>PLCG1</italic> (GenBank: NM_002660.3) who exhibit partially overlapping clinical features including hearing impairment (5/7), ocular pathology (4/7), cardiac defects (3/6), abnormal brain MRI findings (2/3), and immunological issues with diverse manifestations (5/7). Utilizing <italic>Drosophila</italic> to model the variants <italic>in vivo</italic>, we provide evidence that the missense <italic>PLCG1</italic> variants are toxic and affect protein function to varying degrees. We argue that these variants contribute to the clinical symptoms observed in the affected individuals.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Individuals with heterozygous missense variants in <italic>PLCG1</italic> exhibit hearing impairment, cardiac defects, ocular pathology, and immune dysregulation</title>
<p>Seven individuals with heterozygous missense variants in <italic>PLCG1</italic> were recruited trough the Undiagnosed Diseases Network (UDN) (<xref ref-type="bibr" rid="c65">Splinter et al. 2018</xref>) (Individuals 1-2) and GeneMatcher (<xref ref-type="bibr" rid="c64">Sobreira et al. 2015</xref>) (Individuals 3-7). Individuals 1-3 are <italic>de novo</italic> cases from unrelated families: Individual 1 [c.3056A&gt;G, p.(Asp1019Gly)], Individual 2 [c.1139A&gt;G, p.(His380Arg)] and Individual 3 [c.3494A&gt;G, p.(Asp1165Gly)]. Individuals 4-7 are from the same family, and all carry the <italic>PLCG1</italic> variant [c.1789C&gt;T p.(Leu597Phe)]. The phenotypes of the individuals partially overlap but show a spectrum of clinical manifestations. <bold>[<italic>As per medRxiv policy, the whole and detailed case history for the probands have been removed. To obtain more detailed information, please contact the authors]</italic></bold></p>
</sec>
<sec id="s2b">
<title>The missense <italic>PLCG1</italic> variants affect conserved protein domains and are predicted to be deleterious</title>
<p><italic>PLCG1</italic> is predicted to be tolerant to loss-of-function alleles with a pLI score (<xref ref-type="bibr" rid="c39">Lek et al. 2016</xref>) of 0.16, suggesting that loss of one copy of the gene is unlikely to cause haploinsufficiency in humans, consistent with the presence of many protein truncating variants in gnomAD (<xref ref-type="bibr" rid="c33">Karczewski et al. 2020</xref>). However, the missense constraint Z score (<xref ref-type="bibr" rid="c39">Lek et al. 2016</xref>) of <italic>PLCG1</italic> is 3.69, suggesting that it is intolerant to missense variants. Consistently, all variants are located within regions or stretches depleted in missense variants according to scores such as regional missense constraint (RMC) (<xref ref-type="bibr" rid="c10">Chao et al. 2024</xref>) or missense tolerance ratio (MTR) (<xref ref-type="bibr" rid="c68">Sun et al. 2024</xref>). In addition, the prediction based on the DOMINO algorithm indicates that <italic>PLCG1</italic> variants are likely to have a dominant effect (<xref ref-type="bibr" rid="c57">Quinodoz et al. 2017</xref>). Several other <italic>in-silico</italic> pathogenicity predictions also suggest that these variants are likely to be pathogenic (Table S1) based on MARRVEL (<xref ref-type="bibr" rid="c75">Wang et al. 2017</xref>).</p>
<p>The four variants identified from the affected individuals map to different conserved domains of PLCγ1, and each variant affects an amino acid residue that is conserved from flies to humans (<xref rid="fig1" ref-type="fig">Figure 1A</xref> and <xref rid="fig1" ref-type="fig">1B</xref>). The p.(Asp1019Gly) and p.(His380Arg) variants map to the catalytic core domains (X and Y regions, respectively), the p.(Asp1165Gly) variant is in the C-terminal C2 domain and the p.(Leu597Phe) variant is in the nSH2 domain. The latter is part of the PLCγ-specific regulatory array composed of a split PH domain (sPH), two Src homology 2 (nSH2 and cSH2) domains and a Src homology 3 (SH3) domain. PLCγ1 also contains other conserved domains including an N-terminal pleckstrin homology (PH) domain and four EF hand motifs.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>The <italic>PLCG1</italic> ortholog is <italic>small wing</italic> (<italic>sl</italic>) in <italic>Drosophila</italic></title><p>(A) Schematic of human PLCG1 and fly Sl protein domains and positions of the variants identified in the affected individuals. Domain prediction is based on annotation from NCBI.</p><p>(B) Alignment of protein domains near variants of PLCG1 and PLCG2 with PLCG1 from other species. The variants are marked with boxes. All the variants affect conserved amino acids (labeled in red). Isoforms for alignment: Human PLCG1 NP_877963.1; Human PLCG2 NP_002652.2; Mouse Plcg1 NP_067255.2; Zebrafish plcg1 NP_919388.1; Fly sl NP_476726.2.</p><p>(C) Schematic of fly <italic>sl</italic> genomic span, transcript, alleles and the 92kb genomic rescue (GR) construct. Loss-of-function alleles of <italic>sl</italic> including <italic>sl</italic><sup>2</sup> (13bp deletion (<xref ref-type="bibr" rid="c70">Thackeray et al. 1998</xref>)), <italic>sl<sup>KO</sup></italic> (CRISPR-mediated deletion of the gene span (<xref ref-type="bibr" rid="c71">Trivedi et al. 2020</xref>)), and <italic>sl<sup>T2A</sup></italic>(T2A cassette inserted in the first intron, (<xref ref-type="bibr" rid="c38">Lee et al. 2018</xref>)) are indicated. The T2A cassette in <italic>sl<sup>T2A</sup></italic> is flanked by FRT sites and can be excised by Flippase to revert loss-of-function phenotypes. GAL4 expression in <italic>sl<sup>T2A</sup></italic> is driven by the endogenous <italic>sl</italic> promoter, allowing assessment of <italic>sl</italic> gene expression pattern with a <italic>UAS-mCherry.nls</italic> reporter line. This system also allows <italic>in vivo</italic> modeling of proband-associated variants by crossing with human <italic>PLCG1</italic> cDNAs or corresponding fly <italic>sl</italic> cDNAs. The primer pair used for real-time PCR is indicated.</p></caption>
<graphic xlink:href="23300523v2_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2c">
<title>The <italic>small wing</italic> (<italic>sl</italic>) is the fly ortholog of human <italic>PLCG1</italic></title>
<p>Flies have three genes encoding PLC isozymes (Table S2). Among them, <italic>small wing</italic> (<italic>sl</italic>) is predicted to be the ortholog of <italic>PLCG1</italic> with a DIOPT (DRSC Integrative Ortholog Prediction Tool) score of 17/18 (DIOPT version 9.0) (<xref ref-type="bibr" rid="c28">Hu et al. 2021</xref>). The encoded proteins share 39% identity and 57% similarity and are composed of similar conserved domains (<xref rid="fig1" ref-type="fig">Figure 1A</xref>). The <italic>sl</italic> gene is also predicted to be the ortholog of <italic>PLCG2</italic> with a DIOPT score of 12/18. These data suggest that <italic>sl</italic> corresponds to two human genes encoding the PLCγ isozymes. To obtain information about the nature of the <italic>PLCG1</italic> variants, we utilize <italic>Drosophila</italic> to model them <italic>in vivo</italic> using the binary GAL4 system (<xref ref-type="bibr" rid="c9">Brand and Perrimon 1993</xref>). We generated transgenic flies carrying the <italic>UAS-human PLCG1</italic> cDNAs for both the reference (<italic>UAS-PLCG1<sup>Reference</sup></italic>) and the variants (<italic>UAS-PLCG1<sup>D1019G</sup></italic>, <italic>UAS-PLCG1<sup>H380R</sup></italic>, <italic>UAS-PLCG1<sup>D1165G</sup></italic>, and <italic>UAS-PLCG1<sup>L597F</sup></italic>). Given the high level of protein sequence homology and the conservation of the affected amino acids (<xref rid="fig1" ref-type="fig">Figure 1B</xref>), we also generated transgenic flies for the reference and analogous variants in the fly <italic>sl</italic> cDNA, namely <italic>UAS-sl<sup>WT</sup></italic> and <italic>UAS-sl<sup>variants</sup></italic> (<italic>UAS-sl<sup>D1041G</sup></italic>, <italic>UAS-sl<sup>H384R</sup></italic>, <italic>UAS</italic>-<italic>sl<sup>D1184G</sup></italic>, and <italic>UAS-sl<sup>L630F</sup></italic>).</p>
<p>In <italic>Drosophila</italic>, <italic>sl</italic> is on the X chromosome, and several alleles of <italic>sl</italic> have been isolated or previously generated, including <italic>sl<sup>2</sup></italic>, <italic>sl<sup>KO</sup></italic> and <italic>sl<sup>T2A</sup></italic>(<xref rid="fig1" ref-type="fig">Figure 1C</xref>). <italic>sl<sup>2</sup></italic> carries a 13bp deletion in the third exon that leads to a frameshift and early stop gain (<xref ref-type="bibr" rid="c70">Thackeray et al. 1998</xref>). <italic>sl<sup>2</sup></italic> is a strong loss-of-function allele that causes small wing size, ectopic wing veins and extra R7 photoreceptors (<xref ref-type="bibr" rid="c70">Thackeray et al. 1998</xref>). <italic>sl<sup>KO</sup></italic> was generated by CRISPR-mediated genomic editing that removes nearly the entire gene (<xref ref-type="bibr" rid="c71">Trivedi et al. 2020</xref>). <italic>sl<sup>T2A</sup></italic> allele was generated by inserting an FRT-SA-T2A-GAL4-polyA-FRT cassette as an artificial exon into the first coding intron of <italic>sl</italic> (<xref rid="fig1" ref-type="fig">Figure 1C</xref>) (<xref ref-type="bibr" rid="c14">Diao et al. 2015</xref>; <xref ref-type="bibr" rid="c38">Lee et al. 2018</xref>). The polyA arrests transcription, and <italic>sl<sup>T2A</sup></italic> is a strong loss-of-function allele (Figure S1A). The T2A viral sequence triggers ribosomal skipping and leads to the production of GAL4 proteins (<xref ref-type="bibr" rid="c16">Donnelly et al. 2001</xref>; <xref ref-type="bibr" rid="c15">Diao and White 2012</xref>) that are expressed in the proper spatial and temporal pattern of <italic>sl</italic>. This allows us to assess the expression pattern of <italic>sl</italic> by driving the expression of a <italic>UAS-fluorescent protein</italic> (<xref ref-type="bibr" rid="c38">Lee et al. 2018</xref>), or to assess the function of variants by expressing the human <italic>UAS-reference/variant cDNAs</italic> (<xref ref-type="bibr" rid="c29">Huang et al. 2022a</xref>; <xref ref-type="bibr" rid="c30">Huang et al. 2022b</xref>; <xref ref-type="bibr" rid="c42">Lu et al. 2022a</xref>; <xref ref-type="bibr" rid="c43">Lu et al. 2022b</xref>; <xref ref-type="bibr" rid="c44">Ma et al. 2023</xref>; <xref ref-type="bibr" rid="c54">Pan et al. 2023</xref>). In addition, the cassette is flanked by two FRT sites and can therefore be excised from the cells that express the gene in the presence of <italic>UAS-Flippase</italic> to revert the mutant phenotypes (<xref rid="fig1" ref-type="fig">Figure 1C</xref>) (<xref ref-type="bibr" rid="c38">Lee et al. 2018</xref>).</p>
<p>We first assessed the expression pattern of <italic>sl</italic> by driving <italic>UAS-mCherry.nls</italic> (an mCherry that localizes to nuclei) with <italic>sl<sup>T2A</sup></italic>. <italic>sl</italic> is expressed in the 3<sup>rd</sup> larval wing discs and eye discs (<xref rid="fig2" ref-type="fig">Figure 2A</xref>), consistent with the loss-of-function phenotypes observed in the wings and eyes (<xref ref-type="bibr" rid="c70">Thackeray et al. 1998</xref>). The expression pattern of <italic>sl</italic> in the wing discs is not homogenous. Higher expression levels are observed in the anterior compartment and along both the anterior/posterior and dorsal/ventral compartment boundaries (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). The hemizygous <italic>sl<sup>T2A</sup>/Y</italic> male flies and the trans-heterozygous <italic>sl<sup>T2A</sup>/sl<sup>2</sup></italic> or <italic>sl<sup>T2A</sup>/sl<sup>KO</sup></italic>female flies show reduced wing size and ectopic wing veins (<xref rid="fig2" ref-type="fig">Figure 2B</xref> and Figure S1B), as well as additional photoreceptors in the eye (<xref rid="fig2" ref-type="fig">Figure 2C</xref> and Figure S1C). These phenotypes can be rescued by <italic>UAS-Flippase</italic> or by introducing a genomic rescue construct (<italic>Dp(1;3)DC313</italic> (<xref ref-type="bibr" rid="c73">Venken et al. 2010</xref>), <xref rid="fig1" ref-type="fig">Figure 1C</xref>) that covers the <italic>sl</italic> locus (<xref rid="fig2" ref-type="fig">Figure 2B</xref> and <xref rid="fig2" ref-type="fig">Figure 2C</xref>). These data show that all the observed phenotypes in <italic>sl<sup>T2A</sup></italic> mutants can be attributed to the loss of <italic>sl</italic>.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title><italic>sl<sup>T2A</sup></italic> is a loss-of-function allele that affect fly wing and eye development</title><p>(A) <italic>sl</italic> expression in wing and eye dises. Expression of <italic>UAS-mcherry.nls</italic> (red) was driven by <italic>sl<sup>T2A</sup></italic>to label the nuclei of the cells that expressed <italic>sl</italic>. <italic>sl</italic> is expressed in the 3rd instar larval wing disc (left) and eye disc (right). Higher magnification image of the wing disc pouch region indicated by dashed rectangle is shown. The posterior/anterior and dorsal/ventral compartment boundaries are indicated by dashed lines in yellow. Scale bars, 100μm</p><p>(B) <italic>sl<sup>T2A</sup></italic> causes a wing size reduction and ectopic veins (arrowhead) in hemizygous mutant male flies. The wing phenotypes can be rescued by introduction of a genomic rescue (GR) construct or the expression of Flippase. Scale bars, 0.5mm. The quantification of adult wing size is shown in the right panel. Each dot represents the measurement of one adult wing sample. Unpaired t test, ∗∗∗∗p &lt; 0.0001, mean ± SEM.</p><p>(C) <italic>sl<sup>T2A</sup></italic> causes extra photoreceptors (arrows) in the hemizygous mutant flies. The eye phenotype can be rescued by introduction of a genomic rescue (GR) construct. The photoreceptor rhabdomeres stain positive for phalloidin labeling F-actin. Scale bars, 10μm. The quantification is shown in the right panel. Each dot represents the measurement of one retina sample. Unpaired t test, ∗∗∗∗p &lt; 0.0001, mean ± SEM.</p></caption>
<graphic xlink:href="23300523v2_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2d">
<title>The <italic>sl</italic> gene is expressed in the fly CNS and loss of <italic>sl</italic> causes longevity and locomotion defects</title>
<p>Given that human <italic>PLCG1</italic> is highly expressed in the central nervous system (CNS) (<xref ref-type="bibr" rid="c12">Consortium 2015</xref>) and that the affected individuals present with neurologic phenotypes including hearing or vision deficits (Table 1), we investigated the expression pattern and the cell type specificity of <italic>sl</italic> in the CNS of flies. <italic>sl</italic> is expressed in the larval CNS as well as the adult brain, and co-staining with the pan-neuronal marker Elav (<xref ref-type="bibr" rid="c60">Robinow and White 1991</xref>) and glial marker Repo (<xref ref-type="bibr" rid="c61">Sepp et al. 2001</xref>) show that <italic>sl</italic> is expressed in many neurons and glia cells in the CNS (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). We therefore assessed the longevity and climbing of <italic>sl<sup>T2A</sup></italic> flies. Compared to the wild-type <italic>w<sup>1118</sup></italic> flies, <italic>sl<sup>T2A</sup>/Y</italic> hemizygous mutant flies show a shortened lifespan and a progressively reduced climbing ability. These phenotypes can be rescued by expression of the wild-type <italic>sl</italic> cDNA(<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>WT</sup></italic>) (<xref rid="fig3" ref-type="fig">Figure 3B</xref>).</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title><italic>sl</italic> is expressed in a subset of neurons and glia in the CNS, and loss of <italic>sl</italic> causes behavioral defects</title><p>(A) Expression pattern of <italic>sl</italic> in the central nervous system observed by <italic>sl<sup>T2A</sup></italic>-driven expression of <italic>UAS-mCherry.nls</italic> reporter (red). In either larval or adult brain, <italic>sl</italic> is expressed in a subset of fly neurons and glia, which were labeled by pan-neuronal marker Elav (green, upper panel) and pan-glia marker Repo (green, lower panel). Higher magnification images of the regions indicated by dashed rectangles are shown. Scale bars, 20μm in the magnified images, 50μm in other images.</p><p>(B) Loss of <italic>sl</italic> causes defects in longevity and locomotion. <italic>sl<sup>T2A</sup></italic> hemizygous flies have a shorter lifespan than <italic>w<sup>1118</sup></italic> control flies. The median lifespan of <italic>sl<sup>T2A</sup></italic> and <italic>w<sup>1118</sup></italic> flies is 40 days and 62 days respectively. The shorter lifespan of <italic>sl<sup>T2A</sup></italic> flies can be rescued by a UAS transgene that expresses the wild-type <italic>sl</italic> cDNA (<italic>sl<sup>WT</sup></italic>). Fly locomotion was assessed by climbing assay (see methods). <italic>sl<sup>T2A</sup></italic>flies at the age of 7 days show reduced locomotion and become almost immotile at the age of 35 days. The reduced locomotion ability in <italic>sl<sup>T2A</sup></italic> flies can be fully rescued by <italic>sl<sup>WT</sup></italic>. For lifespan assay, Longrank test, ****p&lt;0.0001. For climbing assay, each dot represents measurement of one vial containing 18-22 flies for test. Unpaired t test, ****p&lt;0.0001.</p></caption>
<graphic xlink:href="23300523v2_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2e">
<title>Functional assays in flies indicate that the <italic>PLCG1</italic> variants are toxic</title>
<p>To assess the impact of the variants, we expressed the <italic>sl</italic> variant cDNAs in the <italic>sl<sup>T2A</sup>/Y</italic> hemizygous mutant males(<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>variants</sup></italic>) and compared their rescue ability with the wild-type <italic>sl</italic>(<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>WT</sup></italic>). As shown in <xref rid="fig4" ref-type="fig">Figure 4A</xref> (middle panel), the <italic>sl<sup>T2A</sup>/Y</italic> mutant flies (or the ones expressing a <italic>UAS-Empty</italic> control construct) have a slightly reduced eclosion rate, but expression of the <italic>sl<sup>WT</sup></italic> cDNA fully rescues the percentage of eclosing progeny as measured by the Mendelian ratio. In contrast, expression of <italic>sl<sup>L630F</sup></italic> (<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>L630F</sup></italic>) reduced the percentage of hemizygous male progeny from the expected 25% to approximately 17%, while expression of <italic>sl<sup>H384R</sup></italic> causes a severe reduction in the number of eclosing flies, with only a few escapers (<italic>sl<sup>T2A</sup>/Y; UAS-sl<sup>H384R</sup></italic>). Expression of the <italic>sl<sup>D1041G</sup></italic> or <italic>sl<sup>D1184G</sup></italic> leads to 100% lethality. These data clearly indicate that these variants are toxic but at different levels.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>The human and corresponding fly variants are toxic when expressed in flies</title><p>(A) Summary of the viability associated with expression of <italic>sl</italic> cDNAs in <italic>sl<sup>T2A</sup></italic> mutant or heterozygous flies. Cross strategy: heterozygous <italic>sl<sup>T2A</sup></italic> female flies were crossed to male flies carrying <italic>UAS-cDNAs</italic> or control (<italic>UAS-Empty</italic>) constructs, or crossed to the <italic>y w</italic> males as an extra control. The percentages of hemizygous <italic>sl<sup>T2A</sup>/Y</italic> male progeny (red) or <italic>sl<sup>T2A</sup>/yw</italic> heterozygous female progeny (blue) that express different <italic>UAS-cDNA</italic> constructs were calculated. The expected Mendelian ratio is 0.25 (indicated by the green line in the graph). The fly analogue variants of the proband-associated variants were tested. Each dot represents one independent replicate. Unpaired t test, *p&lt;0.05, **p &lt; 0.01, ****p &lt; 0.0001, ns: not significant, mean ± SEM.</p><p>(B) Summary of the viability associated with the expression of <italic>PLCG1</italic> cDNAs in <italic>sl<sup>T2A</sup></italic> mutant (red, males) or heterozygous (blue, females) flies. The same cross strategy and progeny ratio measurement described in (A) were applied. The proband-associated variants as well as three previously reported <italic>PLCG1</italic> variants were assessed. We also included the <italic>PLCG2</italic> reference cDNA. Each dot represents one independent replicate. Unpaired t test, *p&lt;0.05, **p &lt; 0.01, ns: not significant, mean ± SEM.</p></caption>
<graphic xlink:href="23300523v2_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Since the <italic>sl<sup>T2A</sup>/Y; UAS-cDNA</italic> hemizygous males lack the endogenous <italic>sl<sup>+</sup>,</italic> we tested <italic>sl<sup>T2A</sup>/yw; UAS-cDNA</italic> heterozygous female flies that carry a copy of wild-type <italic>sl<sup>+</sup></italic> while simultaneously expressing <italic>UAS-cDNAs</italic> driven by the <italic>sl<sup>T2A</sup></italic> driver in the cells that endogenously express <italic>sl</italic> (<xref rid="fig4" ref-type="fig">Figure 4A</xref>, right panel). The eclosion rates of heterozygous female progeny expressing <italic>sl</italic> variants were significantly reduced compared to those expressing <italic>sl<sup>WT</sup></italic>. Expression of <italic>sl<sup>H384R</sup></italic> or <italic>sl<sup>L630F</sup></italic> in the heterozygous progeny reduced the expected 25% proportion to approximately 10% and 20%, respectively, whereas expression of <italic>sl<sup>D1041G</sup></italic> or <italic>sl<sup>D1184G</sup></italic>resulted in complete lethality in heterozygous flies. These results suggest that the missense variants exert a dominant toxic effect. Additionally, we observed that the toxicity may have both developmental and acute effects in adults, with varying severity among the different variants (Figure S2), indicating that <italic>sl</italic> function is required in adult flies, implying that <italic>PLCG1</italic> variants may cause long-term deficits in affected individuals.</p>
<p>To compare the <italic>sl</italic> and <italic>PLCG1</italic> associated phenotypes, we conducted similar assays using human <italic>PLCG1</italic> cDNAs (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). Expression of <italic>PLCG1<sup>Reference</sup></italic> in the <italic>sl<sup>T2A</sup>/Y</italic> mutant flies (<italic>sl<sup>T2A</sup>/Y; UAS-PLCG1<sup>Reference</sup></italic>) reduces viability by 80%, and expression of the other PLCγ coding gene, <italic>PLCG2</italic>, is also toxic and causes similar viability reduction compared to <italic>PLCG1<sup>Reference</sup></italic>. This suggests that expression of human PLCγ genes is toxic in flies. This toxicity appears to be associated with expression level (Figure S3), and the survivals of <italic>sl<sup>T2A</sup>/Y; UAS-PLCG1<sup>Reference</sup></italic> did not show rescue of the loss-of-function phenotypes in the wings or eyes (Figure S4). Expression of <italic>PLCG1<sup>H380R</sup></italic>or <italic>PLCG1<sup>L597F</sup></italic> in the <italic>sl<sup>T2A</sup>/Y</italic> mutant flies (<italic>sl<sup>T2A</sup>/Y; UAS-PLCG1<sup>H380R</sup></italic>or <italic>sl<sup>T2A</sup>/Y; UAS-PLCG1<sup>L597F</sup></italic>) leads to a significant but very modest increase in lethality when compared to <italic>PLCG1<sup>Reference</sup></italic>, whereas expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic>results in 100% lethality (<xref rid="fig4" ref-type="fig">Figure 4B</xref>, left panel). When the reference and variants are assayed in the presence of a wild type copy of <italic>sl<sup>+</sup>,</italic> the heterozygous female progeny expressing the reference cDNA of <italic>PLCG1</italic> or <italic>PLCG2</italic> exhibited normal eclosion rate, as did the ones expressing <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic>, suggesting that the presence of a wild-type copy of <italic>sl<sup>+</sup></italic> combined with the reduced expression levels (typically 50% due to dosage compensation for the cells on X chromosome) mask some of the potential toxicity. However, expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic>still resulted in complete lethality in the females (<xref rid="fig4" ref-type="fig">Figure 4B</xref>, right panel). In summary, expression of the <italic>PLCG1</italic> variants and the corresponding fly <italic>sl</italic> variants exhibit greater toxicity than the reference or wild-type proteins with varying degrees of severity, suggesting that the variants are likely to be gain-of-function or neomorphic alleles. Among them, the <italic>PLCG1<sup>D1019G</sup></italic> and <italic>sl<sup>D1041G</sup></italic>, as well as <italic>PLCG1<sup>D1165G</sup></italic> and <italic>sl<sup>D1184G</sup></italic> are very strong toxic alleles whereas <italic>PLCG1<sup>H380R</sup>, PLCG1<sup>L597F</sup>,</italic> and their fly analogues are mild variants.</p>
</sec>
<sec id="s2f">
<title>The p.Asp1019Gly and p.Asp1165Gly variants are hyperactive</title>
<p>To assess whether the variants act as gain-of-function alleles that enhance the enzymatic activity of the PLCγ1 isozyme, we tested them using a Ca²D reporter assay. Since one of the products of the PLCγ1 isozyme, IPD, binds to receptors on the endoplasmic reticulum to trigger Ca²D release (<xref ref-type="bibr" rid="c19">Foskett et al. 2007</xref>), intracellular Ca²D levels can serve as a proxy of the PLCγ1 enzymatic activity. We expressed the <italic>CaLexA</italic> (calcium-dependent nuclear import of LexA) reporter (<xref ref-type="bibr" rid="c47">Masuyama et al. 2012</xref>) in the wing disc pouch region using a specific GAL4 driver (<italic>nub-GAL4 &gt; UAS-CaLexA.GFP</italic>) while simultaneously expressing <italic>UAS-PLCG1</italic> cDNAs. We first assessed three control variants: <italic>PLCG1<sup>H380A</sup>, PLCG1<sup>D1165H</sup>,</italic> and <italic>PLCG1<sup>S1021F</sup></italic>. Substitution of His380 with Ala (H380A) has been reported to suppress PIP<sub>2</sub> hydrolysis and IP<sub>3</sub> production (<xref ref-type="bibr" rid="c63">Smith et al. 1994</xref>; <xref ref-type="bibr" rid="c74">Wada et al. 2022</xref>), acting as an enzymatic-dead loss-of-function allele. On the other hand, the p.Asp1165His (D1165H) variant was previously identified as a strong gain-of-function somatic variant in adult T cell leukemia/lymphoma (<xref ref-type="bibr" rid="c35">Kataoka et al. 2015</xref>; <xref ref-type="bibr" rid="c24">Hajicek et al. 2019</xref>; <xref ref-type="bibr" rid="c62">Siraliev-Perez et al. 2022</xref>), and has been documented to cause a dramatic increase in phospholipase activity <italic>in vitro</italic> (<xref ref-type="bibr" rid="c24">Hajicek et al. 2019</xref>; <xref ref-type="bibr" rid="c62">Siraliev-Perez et al. 2022</xref>). The p.Ser1021Phe variant was reported recently in a <italic>de novo</italic> case and was characterized as a gain-of-function germline variant (<xref ref-type="bibr" rid="c69">Tao et al. 2023</xref>). As shown in Figure S5A, the GFP signal of the <italic>CaLexA.GFP</italic> reporter was low in wing discs expressing <italic>PLCG1<sup>H380A</sup></italic>, whereas the signal was significantly enhanced in those expressing <italic>PLCG1<sup>D1165H</sup> or PLCG1<sup>S1021F</sup></italic>, showing that this is a robust assay for detecting increased enzymatic activity. We next tested the variants of the affected individuals. As shown in <xref rid="fig5" ref-type="fig">Figure 5A</xref>, expression of <italic>PLCG1<sup>Reference</sup></italic> did not induce obvious GFP signals, suggesting that the protein is not enzymatically active, possibly because of autoinhibition. Similarly, expression of <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic> did not significantly alter the GFP signal, suggesting that they are not constitutively active. However, expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> markedly increased the GFP signal, similar to the <italic>PLCG1<sup>D1165H</sup></italic>and <italic>PLCG1<sup>S1021F</sup></italic> positive controls (<xref rid="fig5" ref-type="fig">Figure 5A</xref> and S4A). The same observations were made with the fly <italic>sl</italic> variants (Figure S5B). These results indicate that the <italic>PLCG1<sup>D1019G</sup></italic> and <italic>PLCG1<sup>D1165G</sup></italic> variants are hyperactive, whereas the <italic>PLCG1<sup>H380R</sup></italic> and <italic>PLCG1<sup>L597F</sup></italic> variants are not hyperactive based on this assay.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Ectopic expression of <italic>PLCG1</italic> variants causes variable phenotypes</title><p>(A) The Ca<sup>2+</sup> reporter <italic>CaLexA.GFP</italic> was expressed in the wing disc pouch, simultaneously with the <italic>PLCG1</italic> cDNAs. Expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic>caused elevated CaLexA.GFP signal (green), indicating increased intracellular Ca<sup>2+</sup> levels indicating that these variants are hyperactive. Nuclei were labeled with DAPI (blue). Scale bars, 100μm.</p><p>(B) Representative images of the adult wing blades showing the morphological phenotypes caused by wing-specific expression of <italic>PLCG1</italic> cDNAs. Expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> caused severe wing morphology defects including notched margin (arrows) and fused/thickened veins (arrowheads). Expression of <italic>PLCG1<sup>L597F</sup></italic> exhibited partial penetrance (penetration ratio indicated). Expression of <italic>PLCG1<sup>H380R</sup></italic> exhibited very mild phenotypes, comparable to <italic>PLCG1<sup>Reference</sup></italic>. Scale bars, 0.5mm.</p><p>(C) Representative images showing that eye-specific expression of <italic>PLCG1<sup>Reference</sup></italic> or <italic>PLCG1<sup>H380R</sup></italic> causes a ∼15% eye size reduction compared to the <italic>UAS-Empty</italic> control construct, and expression of <italic>PLCG1<sup>L597F</sup></italic> further reduced eye size. Expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic>causes a severe size reduction by ∼30%. Each dot in the quantification graph represents the measurement of one adult eye. Unpaired t test, *p&lt;0.05, ****p &lt; 0.0001, ns: not significant, mean ± SEM. Scale bars, 100μm.</p></caption>
<graphic xlink:href="23300523v2_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2g">
<title>The <italic>PLCG1</italic> variants affect size and morphology of wings and eyes</title>
<p>To further assess the impact of the <italic>PLCG1</italic> variants on normal development, we analyzed the morphology of the adult wings upon wing-specific expression of <italic>PLCG1</italic> or <italic>sl</italic> cDNAs (<italic>nub-GAL4 &gt; UAS-cDNAs</italic>). Interestingly, ectopic expression of either <italic>PLCG1<sup>Reference</sup></italic> or <italic>sl<sup>WT</sup></italic> in the wing disc leads to a ∼10% reduction in adult wing size when compared to the <italic>UAS-Empty</italic> control (Figure S6A). This observation, together with the reduced wing size seen in the loss-of-function context (<xref rid="fig2" ref-type="fig">Figures 2B</xref>), suggests that both reduced and elevated levels of PLCγ1 can impair wing growth. This implies a dosage-dependent regulation on wing growth by the PLCγ1 isozymes, while the underlying mechanism is unknown. Additionally, as shown in <xref rid="fig5" ref-type="fig">Figure 5B</xref> and S6B, approximately 10% of the wings expressing <italic>PLCG1<sup>Reference</sup></italic> exhibit notching along the wing margin, a phenotype not observed in wings expressing <italic>sl<sup>WT</sup></italic>. Expression of <italic>PLCG1<sup>H380R</sup></italic> or <italic>PLCG1<sup>L597F</sup></italic> caused notched wings in approximately 18% and 23% of the flies, respectively (Figure S6B), whereas expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> results in severe wing phenotypes characterized by notched wing margins, fused/thickened veins and reduced wing sizes with &gt;95% penetrance (<xref rid="fig5" ref-type="fig">Figure 5B</xref>). Notably, expression of fly <italic>sl<sup>variants</sup></italic>could lead to similar morphological defects as their corresponding human variants, arguing that these wing phenotypes are due to alterations of PLCG1 or Sl protein function (<xref rid="fig5" ref-type="fig">Figure 5B</xref> and S6C).</p>
<p>We also assessed the effect of expression of human <italic>PLCG1</italic> on eye development using the <italic>eyeless-GAL4</italic> (<italic>ey-GAL4</italic>). Expression of <italic>PLCG1<sup>Reference</sup></italic>or <italic>PLCG1<sup>H380R</sup></italic> in fly eyes leads to a mild reduction in eye size when compared to <italic>UAS-Empty</italic> control (<xref rid="fig5" ref-type="fig">Figure 5C</xref> and S6D). However, expression of <italic>PLCG1<sup>L597F</sup></italic> results in rough eyes that are reduced in size whereas overexpression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic>leads to a more severe eye phenotype (<xref rid="fig5" ref-type="fig">Figure 5C</xref> and S6D). In summary, the eye data are consistent with the wing data, showing that <italic>PLCG1<sup>D1019G</sup></italic> and <italic>PLCG1<sup>D1165G</sup></italic> are more toxic than <italic>PLCG1<sup>Reference</sup></italic>. On the other hand, the toxicity of <italic>PLCG1<sup>H380R</sup></italic> and <italic>PLCG1<sup>L597F</sup></italic>are stronger than the <italic>PLCG1<sup>Reference</sup></italic> but not as severe as <italic>PLCG1<sup>D1019G</sup></italic> and <italic>PLCG1<sup>D1165G</sup></italic>. Interestingly, the morphological defects in wings or eyes caused by ectopic expression of <italic>PLCG1</italic> cDNAs correlate with the expression level (Figure S6E), but do not directly correlate with the phospholipase enzymatic activity. For example, expression of <italic>PLCG1<sup>S1021F</sup></italic> does not cause obvious morphological defects when compared to <italic>PLCG1<sup>Reference</sup></italic> (Figure S6B and S6F), even though <italic>PLCG1<sup>S1021F</sup></italic>is hyperactive and induces significantly elevated intracellular Ca<sup>2+</sup> in the CaLexA reporter assay (Figure S5A).</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Here we report seven individuals who carry heterozygous missense variants in <italic>PLCG1</italic> which encodes the phospholipase C γ1 isozyme. The individuals present with partially overlapping clinical features including hearing impairment, eye abnormality, heart defects and immune phenotypes. We show that the fly ortholog, <italic>small wing</italic> (<italic>sl</italic>), is widely expressed in wings and eyes, as well as in the central nervous system. Consistent with its expression pattern, we report that <italic>sl</italic> not only regulates wing and eye development, as previously documented, but also plays critical roles in the nervous system and affects locomotion and longevity. Furthermore, we assessed the function of the variants in the context of the human and fly cDNAs and show that their expression induces variable levels of toxicity when compared to the reference <italic>PLCG1</italic> or wild-type <italic>sl</italic>. Two of the variants are clearly hyperactive, and all the variants exhibit neomorphic effects (discussed in Supplemental Figure Notes). These observations show that the variants impair the normal function <italic>in vivo</italic> and suggest that they contribute to the symptoms observed in the affected individuals. Similarly to inborn error caused by the paralogous <italic>PLCG2</italic> (<xref ref-type="bibr" rid="c5">Baysac et al. 2024</xref>), germline variants in <italic>PLCG1</italic> can be pathogenic and dominant by different mechanisms.</p>
<sec id="s3a">
<title>Structural analysis of the PLCG1 variants</title>
<p>Previously, studies based on biochemical assays and protein structures provided insights into how the variants studied here may affect the enzymatic activity of PLCγ1 (the protein structure of full-length rat Plcg1 is shown in <xref rid="fig6" ref-type="fig">Figure 6A</xref>). In its basal state, the PLCγ-specific regulatory array (sPH-nSH2-cSH2-SH3) forms autoinhibitory interfaces with the catalytic domains. Upon activation by the RTKs through binding with nSH2, PLCγ1 is phosphorylated, which induces the dissociation of the inhibitory cSH2 domain from the C2 domain. This triggers conformational rearrangements, allowing the enzyme to associate with the membrane and to expose the catalytic domains to allow hydrolysis of PIP2 (<xref ref-type="bibr" rid="c21">Gresset et al. 2010</xref>; <xref ref-type="bibr" rid="c24">Hajicek et al. 2019</xref>; <xref ref-type="bibr" rid="c41">Liu et al. 2020</xref>; <xref ref-type="bibr" rid="c37">Le Huray et al. 2022</xref>; <xref ref-type="bibr" rid="c52">Nosbisch et al. 2022</xref>). As shown in <xref rid="fig6" ref-type="fig">Figure 6A</xref>, the proband-associated variants map to conserved domains of the protein, either within the catalytic domains or at intramolecular and intermolecular interfaces. The p.Asp1019Gly and p.Asp1165Gly variants impact key residues involved in autoinhibition, leading to increased enzymatic activity. Specifically, the p.Asp1019Gly variant affects a conserved residue within the hydrophobic ridge of the Y box (<xref rid="fig6" ref-type="fig">Figure 6B</xref>), which is important for interaction with the sPH domain. This interaction is critical for the autoinhibition by blocking the membrane engagement of the catalytic core domain prior to enzymatic activation (<xref ref-type="bibr" rid="c17">Ellis et al. 1998</xref>; <xref ref-type="bibr" rid="c24">Hajicek et al. 2019</xref>). Notably, a substitution at the same position (Asp1019Lys, D1019K) has been demonstrated to enhance basal phospholipase activity <italic>in vitro</italic> (<xref ref-type="bibr" rid="c23">Hajicek et al. 2013</xref>), supporting its regulatory importance. Similarly, another hotspot somatic variant, p.Ser345Phe, located in the corresponding hydrophobic ridge within the X box, is also hyperactive (<xref ref-type="bibr" rid="c72">Vaque et al. 2014</xref>; <xref ref-type="bibr" rid="c46">Manso et al. 2015</xref>). On the other hand, the p.Asp1165Gly variant affects a residue situated within a loop of the C2 domain (<xref rid="fig6" ref-type="fig">Figure 6C</xref>). The Asp1165 residue plays a key role in stabilizing the interaction between the cSH2 domain and the C2 domain to maintain the autoinhibited state (<xref ref-type="bibr" rid="c13">DeBell et al. 2007</xref>). As mentioned above, the somatic variant p.Asp1165His leads to significantly elevated phospholipase activity <italic>in vitro</italic> (<xref ref-type="bibr" rid="c41">Liu et al. 2020</xref>; <xref ref-type="bibr" rid="c62">Siraliev-Perez et al. 2022</xref>), and results in severe phenotypes <italic>in vivo</italic> (<xref rid="fig4" ref-type="fig">Figure 4B</xref>, S5E and S5F). Molecular dynamics simulation data consistently indicate that autoinhibition is likely disrupted by the p.Asp1019Gly and p.Asp1165Gly variants (Figure S7A). In contrast, the p.His380Arg variant impacts the His380 residue within the X box, situated near a Ca<sup>2+</sup> ion in the catalytic core (<xref rid="fig6" ref-type="fig">Figure 6D</xref>). His380 plays a role in coordination of the phosphate group at the 1-position of IP<sub>3</sub> (<xref ref-type="bibr" rid="c37">Le Huray et al. 2022</xref>). While this residue may not be key to autoinhibition, it is important for the phospholipase activity. Substitution of His380 with Phe or Ala (H380F, H380A) have been reported to suppress PIP<sub>2</sub> hydrolysis and IP<sub>3</sub> production (<xref ref-type="bibr" rid="c63">Smith et al. 1994</xref>; <xref ref-type="bibr" rid="c74">Wada et al. 2022</xref>). Hence, substitution of the His380 with Arg in p.His380Arg variant may create a more basic environment, impacting the lipase activity. On the other hand, the p.Leu597Phe variant affects a residue within the nSH2 domain, which is part of the PLCγ-specific regulatory array (<xref rid="fig6" ref-type="fig">Figure 6E</xref>). The nSH2 domain mediates interactions with phosphorylated tyrosine residues on RTKs to initiate activation (<xref ref-type="bibr" rid="c3">Bae et al. 2009</xref>). Leu597 is located near the phosphotyrosine-binding pocket and this variant may therefore alter receptor specificity or induce novel protein interactions. Additionally, we utilized the DDMut platform (<xref ref-type="bibr" rid="c80">Zhou et al. 2023</xref>) to predict protein stability and folding of the variants, which are discussed in Figure S7B. In summary, our <italic>in vivo</italic> data are consistent with previous reports and <italic>in silico</italic> analyses, showing that the affected amino acids map to critical residues and strengthening the conclusion that the variants are pathogenic and likely impact the protein function through distinct mechanisms.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title><italic>PLCG1</italic> variants affect important residues</title><p>(A) 3D structure of full-length rat Plcg1 (rat Plcg1 shares 97% amino acid identity with human PLCG1). The conserved protein domains are labeled with different colors. Two major intracellular interfaces are circled by dashed lines: 1-The hydrophobic ridge between the sPH domain and the catalytic core (X-box and Y-box); and 2-The interface between the cSH2 domain and the C2 domain. The four amino acids affected by the variants are shown as bolded black and indicated by yellow balls.</p><p>(B) Enlarged views of the Asp1019 residue within the autoinhibition interface between sPH domain and the Y box. The potential interactions with nearby residues are indicated.</p><p>(C) Enlarged view of the Asp1165 residue within the autoinhibition interface between the cSH2 domain and the C2 domain. The potential interactions with nearby residues are indicated.</p><p>(D) Enlarged view of the His380 residue within the X-box catalytic domain, in proximity to the Ca<sup>2+</sup> cofactor.</p><p>(E) Enlarged view of the Leu597 and nearby residues in the nSH2 domain. Structural analysis was performed via UCSF Chimera (<xref ref-type="bibr" rid="c56">Pettersen et al. 2004</xref>)</p></caption>
<graphic xlink:href="23300523v2_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s3b">
<title>The <italic>PLCG1</italic> variants affect protein function to varying degrees and are associated with variable clinical manifestations</title>
<p>To better assess the genotype-phenotype relationship of the variants, we summarize the clinical features of affected individuals in Table 1, and the phenotypic effects observed in fly assays in Table S3. The p.(Asp1019Gly) (carried by Individual 1) and p.(Asp1165Gly) (carried by Individual 3) variants and their corresponding fly variants induce severe phenotypes across all assays performed. Individuals 1 and 3 share several obvious clinical features including hearing loss and heart septal defect. In contrast, the p.(His380Arg) and p.(Leu597Phe) variants cause mild or partially penetrant phenotypes across the different fly assays. Individual 2 who carries the p.(His380Arg) variant does not exhibit hearing impairment or heart defects observed in Individuals 1 and 3, but has eye malformations and neuroinflammation features that are shared with individuals 1 and 3, although the ocular and immunological defects manifest differently among individuals. Interestingly, individuals 4-7 are from the same family and all carry the p.(Leu597Phe) variant but also differ in their phenotypes, yet all share some clinical features with Individuals 1-3 (Table 1).</p>
<p>The heterogeneity in clinical manifestations may be influenced by additional genetic variants (see Table 1 legend) and environmental factors. Additionally, the variable expressivity observed in carriers of the same variant may be explained by allelic expression bias through autosomal random monoallelic expression (aRME) (<xref ref-type="bibr" rid="c59">Reinius and Sandberg 2015</xref>), a phenomenon that is thought to be common among carriers of genetic defects associated with inborn errors of immunity (IEIs). Indeed, these conditions often exhibit non-Mendelian segregation patterns and variable clinical features (Stewart et al., 2025). Moreover, the PLCγ1 isozyme is an integral component of multiple signaling pathways, and the consequences of its dysregulation are likely to be context dependent. It is likely that different <italic>PLCG1</italic> variants impact distinct cellular processes across various tissues and cell types, resulting in a spectrum of pathological changes. In summary, the symptoms observed in affected individuals appear to correlate, to some extent, with the severity of the variants as indicated by fly assays. However, the penetrance and expressivity of these phenotypes will require further investigation to better understand the genotype-phenotype associations of <italic>PLCG1</italic> variants.</p>
</sec>
</sec>
</body>
<back>

<ack>
<title>Acknowledgments</title>
<p>We thank the individuals and families for their participation in this study. We thank Ms. Hongling Pan for helping in the generation of transgenic fly lines. We thank Dr. Meisheng Ma for suggestions about protein structure interpretation. We thank Dr. Zhandong Liu for providing computational resources for performing the molecular dynamics simulations. We thank the Bloomington Drosophila Stock Center (BDSC) for providing stocks.</p>
</ack>
<sec id="d1e2871" sec-type="additional-information">
<title>Additional information</title>
<sec id="s4" sec-type="data-availability">
<title>Data and code availability</title>
<p>This study did not generate datasets. All reagents developed in this study are available upon request.</p>
</sec>
<sec id="s6">
<title>Funding Statement</title>
<p>This work was supported by the Huffington Foundation; the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and the Undiagnosed Diseases Network funded by grants from the National Institutes of Health (U01 HG010233, U01 NS134355, U01 HG007709, U01 HG007942). Sequence data analysis was supported by the University of Washington Center for Rare Disease Research (UW-CRDR; U01 HG011744, UM1 HG006493, U24 HG011746). The content of this paper is the sole responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. H.J.B. receives support from the NIH Common Fund through the Office of Strategic Coordination/Office of the NIH Director and the NINDS (U54 NS093793) as well as ORIP (R24 OD022005 and R24 OD031447). Confocal microscopy was performed in the BCM IDDRC Neurovisualization Core, supported by the NICHD (U54 HD083092).</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>Conceptualization: M.M., Y.Z., S.R.L., I.A.G., P.P., J.R., S.M., H.J.B.; Data curation: M.M., Y.Z., S.R.L., I.A.G., E.B., P.P., S.M., H.J.B.; Formal analysis: M.M., Y.Z., S.L., J.A.R., A.A., M.D., X.L., P.B.; Funding acquisition: UDN, H.J.B.; Investigation: M.M., Y.Z., S.L., M.D., D.L., M.E.; Resources: M.M., Y.Z., D.L., K.W.C., B.L.C., B.L.S., M.G., M.B., S.Y., M.F.W., S.R.L., I.A.G., P.P., J.R., S.M., H.J.B.; Supervision: H.J.B.; Visualization: M.M., Y.Z., M.D., S.L., X.P. L.D.; Writing-original draft: M.M., Y.Z.; Writing-review &amp; editing: M.M., Y.Z., M.D., X.L., X.P., S.L., D.L., D.D., J.A.R., J.C., W-L.C., E.B., S.R.L., I.A.G., P.P., S.M., H.J.B..</p>
</sec>
<sec id="s8">
<title>The Undiagnosed Diseases Network Consortia (Version 3.31.25)</title>
<p>Alyssa A. Tran, Arjun Tarakad, Ashok Balasubramanyam, Brendan H. Lee, Carlos A. Bacino, Daryl A. Scott, Elaine Seto, Gary D. Clark, Hongzheng Dai, Hsiao-Tuan Chao, Ivan Chinn, James P. Orengo, Jennifer E. Posey, Jill A. Rosenfeld, Kim Worley, Lindsay C. Burrage, Lisa T. Emrick, Lorraine Potocki, Monika Weisz Hubshman, Richard A. Lewis, Ronit Marom, Seema R. Lalani, Shamika Ketkar, Tiphanie P. Vogel, William J. Craigen, Jared Sninsky, Lauren Blieden, Sandesh Nagamani, Hugo J. Bellen, Michael F. Wangler, Oguz Kanca, Shinya Yamamoto, Christine M. Eng, Patricia A. Ward, Pengfei Liu, Adeline Vanderver, Cara Skraban, Edward Behrens, Gonench Kilich, Kathleen Sullivan, Kelly Hassey, Ramakrishnan Rajagopalan, Rebecca Ganetzky, Vishnu Cuddapah, Anna Raper, Daniel J. Rader, Giorgio Sirugo, Vaidehi Jobanputra, Allyn McConkie-Rosell, Kelly Schoch, Mohamad Mikati, Nicole M. Walley, Rebecca C. Spillmann, Vandana Shashi, Alan H. Beggs, Calum A. MacRae, David A. Sweetser, Deepak A. Rao, Edwin K. Silverman, Elizabeth L. Fieg, Frances High, Gerard T. Berry, Ingrid A. Holm, J. Carl Pallais, Joan M. Stoler, Joseph Loscalzo, Lance H. Rodan, Laurel A. Cobban, Lauren C. Briere, Matthew Coggins, Melissa Walker, Richard L. Maas, Susan Korrick, Jessica Douglas, Cecilia Esteves, Emily Glanton, Isaac S. Kohane, Kimberly LeBlanc, Rachel Mahoney, Shamil R. Sunyaev, Shilpa N. Kobren, Brett H. Graham, Erin Conboy, Francesco Vetrini, Kayla M. Treat, Khurram Liaqat, Lili Mantcheva, Stephanie M. Ware, Breanna Mitchell, Brendan C. Lanpher, Devin Oglesbee, Eric Klee, Filippo Pinto e Vairo, Ian R. Lanza, Kahlen Darr, Lindsay Mulvihill, Lisa Schimmenti, Queenie Tan, Surendra Dasari, Abdul Elkadri, Brett Bordini, Donald Basel, James Verbsky, Julie McCarrier, Michael Muriello, Michael Zimmermann, Adriana Rebelo, Carson A. Smith, Deborah Barbouth, Guney Bademci, Joanna M. Gonzalez, Kumarie Latchman, LéShon Peart, Mustafa Tekin, Nicholas Borja, Stephan Zuchner, Stephanie Bivona, Willa Thorson, Herman Taylor, Rakale C. Quarells, Ayuko Iverson, Bruce Gelb, Charlotte Cunningham-Rundles, Eric Gayle, Joanna Jen, Louise Bier, Mafalda Barbosa, Manisha Balwani, Mariya Shadrina, Rachel Evard, Saskia Shuman, Susan Shin, Andrea Gropman, Barbara N. Pusey Swerdzewski, Camilo Toro, Colleen E. Wahl, Donna Novacic, Ellen F. Macnamara, John J. Mulvihill, Maria T. Acosta, Precilla D’Souza, Valerie V. Maduro, Ben Afzali, Ben Solomon, Cynthia J. Tifft, David R. Adams, Elizabeth A. Burke, Francis Rossignol, Heidi Wood, Jiayu Fu, Joie Davis, Leoyklang Petcharet, Lynne A. Wolfe, Margaret Delgado, Marie Morimoto, Marla Sabaii, MayChristine V. Malicdan, Neil Hanchard, Orpa Jean-Marie, Wendy Introne, William A. Gahl, Yan Huang, Andrew Stergachis, Danny Miller, Elisabeth Rosenthal, Elizabeth Blue, Elsa Balton, Emily Shelkowitz, Eric Allenspach, Fuki M. Hisama, Gail P. Jarvik, Ghayda Mirzaa, Ian Glass, Kathleen A. Leppig, Katrina Dipple, Mark Wener, Martha Horike-Pyne, Michael Bamshad, Peter Byers, Runjun Kumar, Seth Perlman, Sirisak Chanprasert, Virginia Sybert, Wendy Raskind, Nitsuh K. Dargie, Chun-Hung Chan, Dr. Francisco Bustos velasq, Isum Ward, Jason Schend, Jennifer Morgan, Megan Bell, Miranda Leitheiser, Mohamad Saifeddine, Paul Berger, Rachel Li, Taylor Beagle, Alexander Miller, Beatriz Anguiano, Beth A. Martin, Brianna Tucker, Chloe M. Reuter, Devon Bonner, Elijah Kravets, Hector Rodrigo Mendez, Holly K. Tabor, Jacinda B. Sampson, Jason Hom, Jennefer N. Kohler, Jennifer Schymick, John E. Gorzynski, Jonathan A. Bernstein, Kevin S. Smith, Laura Keehan, Laurens Wiel, Matthew T. Wheeler, Meghan C. Halley, Mia Levanto, Page C. Goddard, Paul G. Fisher, Rachel A. Ungar, Raquel L. Alvarez, Sara Emami, Shruti Marwaha, Stephen B Montgomery, Suha Bachir, Tanner D Jensen, Taylor Maurer, Terra R. Coakley, Euan A. Ashley, Ali Al-Beshri, Anna Hurst, Brandon M Wilk, Bruce Korf, Elizabeth A Worthey, Kaitlin Callaway, Martin Rodriguez, Tammi Skelton, Tarun KK Mamidi, Andrew B. Crouse, Jordan Whitlock, Mariko Nakano-Okuno, Matthew Might, William E. Byrd, Albert R. La Spada, Changrui Xiao, Elizabeth C. Chao, Eric Vilain, Jose Abdenur, Kirsten Blanco, Maija-Rikka Steenari, Rebekah Barrick, Richard Chang, Sanaz Attaripour, Suzanne Sandmeyer, Tahseen Mozaffar, Alden Huang, Andres Vargas, Bianca E. Russell, Brent L. Fogel, Esteban C. Dell’Angelica, George Carvalho, Julian A. Martínez-Agosto, Layal F. Abi Farraj, Manish J. Butte, Martin G. Martin, Naghmeh Dorrani, Neil H. Parker, Rosario I. Corona, Stanley F. Nelson, Yigit Karasozen, Aaron Quinlan, Alistair Ward, Ashley Andrews, Corrine K. Welt, Dave Viskochil, Erin E. Baldwin, John Carey, Justin Alvey, Laura Pace, Lorenzo Botto, Nicola Longo, Paolo Moretti, Rebecca Overbury, Russell Butterfield, Steven Boyden, Thomas J. Nicholas, Matt Velinder, Gabor Marth, Pinar Bayrak-Toydemir, Rong Mao, Monte Westerfield, Brian Corner, John A. Phillips III, Kimberly Ezell, Lynette Rives, Rizwan Hamid, Serena Neumann, Ashley McMinn, Joy D. Cogan, Thomas Cassini, Alex Paul, Dana Kiley, Daniel Wegner, Erin McRoy, Jennifer Wambach, Kathy Sisco, Patricia Dickson, F. Sessions Cole, Dustin Baldridge, Jimann Shin, Lilianna Solnica-Krezel, Stephen C. Pak, Timothy Schedl, Allen Bale, Carol Oladele, Caroline Hendry, Emily Wang, Hua Xu, Hui Zhang, Lauren Jeffries, María José Ortuño Romero, Mark Gerstein, Michele Spencer-Manzon, Monkol Lek, Nada Derar, Odelya Kaufman, Shrikant Mane, Teodoro Jerves Serrano, Vasilis Vasiliou, Winston Halstead, Yong-Hui Jiang</p>
</sec>
</sec>
<sec id="suppd1e2871" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="d1e2855">
<label>Supplemental Tables</label>
<media xlink:href="supplements/300523_file09.xlsx"/>
</supplementary-material>
<supplementary-material id="d1e2862">
<label>Supplemental Figures, Methods and Materials</label>
<media xlink:href="supplements/300523_file10.docx"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arteaga</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Todderud</surname> <given-names>G</given-names></string-name>, <string-name><surname>Coffey</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Carpenter</surname> <given-names>G</given-names></string-name>, <string-name><surname>Page</surname> <given-names>DL</given-names></string-name></person-group> (<year>1991</year>) <article-title>Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>88</volume>:<fpage>10435</fpage>–<lpage>10439</lpage></mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asano</surname> <given-names>S</given-names></string-name>, <string-name><surname>Maetani</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ago</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kanematsu</surname> <given-names>T</given-names></string-name></person-group> (<year>2022</year>) <article-title>Phospholipase C-related catalytically inactive protein enhances cisplatin-induced apoptotic cell death</article-title>. <source>Eur J Pharmacol</source> <volume>933</volume>:<fpage>175273</fpage></mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bae</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Lew</surname> <given-names>ED</given-names></string-name>, <string-name><surname>Yuzawa</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tome</surname> <given-names>F</given-names></string-name>, <string-name><surname>Lax</surname> <given-names>I</given-names></string-name>, <string-name><surname>Schlessinger</surname> <given-names>J</given-names></string-name></person-group> (<year>2009</year>) <article-title>The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site</article-title>. <source>Cell</source> <volume>138</volume>:<fpage>514</fpage>–<lpage>524</lpage></mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balla</surname> <given-names>T</given-names></string-name></person-group> (<year>2013</year>) <article-title>Phosphoinositides: tiny lipids with giant impact on cell regulation</article-title>. <source>Physiol Rev</source> <volume>93</volume>:<fpage>1019</fpage>–<lpage>1137</lpage></mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baysac</surname> <given-names>K</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>G</given-names></string-name>, <string-name><surname>Nakano</surname> <given-names>H</given-names></string-name>, <string-name><surname>Schmitz</surname> <given-names>EG</given-names></string-name>, <string-name><surname>Cruz</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Fisher</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bailey</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Group</surname> <given-names>PL-IDW</given-names></string-name>, <string-name><surname>Mace</surname> <given-names>E</given-names></string-name>, <string-name><surname>Milner</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Ombrello</surname> <given-names>MJ</given-names></string-name></person-group> (<year>2024</year>) <article-title>PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants</article-title>. <source>J Allergy Clin Immunol</source> <volume>153</volume>:<fpage>230</fpage>–<lpage>242</lpage></mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behjati</surname> <given-names>S</given-names></string-name>, <string-name><surname>Tarpey</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Sheldon</surname> <given-names>H</given-names></string-name>, <string-name><surname>Martincorena</surname> <given-names>I</given-names></string-name>, <string-name><surname>Van Loo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Gundem</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wedge</surname> <given-names>DC</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Recurrent PTPRB and PLCG1 mutations in angiosarcoma</article-title>. <source>Nat Genet</source> <volume>46</volume>:<fpage>376</fpage>–<lpage>379</lpage></mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berridge</surname> <given-names>MJ</given-names></string-name></person-group> (<year>1993</year>) <article-title>Inositol trisphosphate and calcium signalling</article-title>. <source>Nature</source> <volume>361</volume>:<fpage>315</fpage>–<lpage>325</lpage></mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berridge</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Irvine</surname> <given-names>RF</given-names></string-name></person-group> (<year>1984</year>) <article-title>Inositol trisphosphate, a novel second messenger in cellular signal transduction</article-title>. <source>Nature</source> <volume>312</volume>:<fpage>315</fpage>–<lpage>321</lpage></mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brand</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Perrimon</surname> <given-names>N</given-names></string-name></person-group> (<year>1993</year>) <article-title>Targeted gene expression as a means of altering cell fates and generating dominant phenotypes</article-title>. <source>Development</source> <volume>118</volume>:<fpage>401</fpage>–<lpage>415</lpage></mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Chao</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Panchal</surname> <given-names>R</given-names></string-name>, <string-name><surname>Liao</surname> <given-names>C</given-names></string-name>, <string-name><surname>Abderrazzaq</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ye</surname> <given-names>R</given-names></string-name>, <string-name><surname>Schultz</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>The landscape of regional missense mutational intolerance quantified from 125,748 exomes</article-title>. <source>bioRxiv</source></mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cocco</surname> <given-names>L</given-names></string-name>, <string-name><surname>Follo</surname> <given-names>MY</given-names></string-name>, <string-name><surname>Manzoli</surname> <given-names>L</given-names></string-name>, <string-name><surname>Suh</surname> <given-names>PG</given-names></string-name></person-group> (<year>2015</year>) <article-title>Phosphoinositide-specific phospholipase C in health and disease</article-title>. <source>J Lipid Res</source> <volume>56</volume>:<fpage>1853</fpage>–<lpage>1860</lpage></mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Consortium</surname> <given-names>G</given-names></string-name></person-group> (<year>2015</year>) <article-title>Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans</article-title>. <source>Science</source> <volume>348</volume>:<fpage>648</fpage>–<lpage>660</lpage></mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DeBell</surname> <given-names>K</given-names></string-name>, <string-name><surname>Graham</surname> <given-names>L</given-names></string-name>, <string-name><surname>Reischl</surname> <given-names>I</given-names></string-name>, <string-name><surname>Serrano</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bonvini</surname> <given-names>E</given-names></string-name>, <string-name><surname>Rellahan</surname> <given-names>B</given-names></string-name></person-group> (<year>2007</year>) <article-title>Intramolecular regulation of phospholipase C-gamma1 by its C-terminal Src homology 2 domain</article-title>. <source>Mol Cell Biol</source> <volume>27</volume>:<fpage>854</fpage>–<lpage>863</lpage></mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diao</surname> <given-names>F</given-names></string-name>, <string-name><surname>Ironfield</surname> <given-names>H</given-names></string-name>, <string-name><surname>Luan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Diao</surname> <given-names>F</given-names></string-name>, <string-name><surname>Shropshire</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Ewer</surname> <given-names>J</given-names></string-name>, <string-name><surname>Marr</surname> <given-names>E</given-names></string-name>, <string-name><surname>Potter</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Landgraf</surname> <given-names>M</given-names></string-name>, <string-name><surname>White</surname> <given-names>BH</given-names></string-name></person-group> (<year>2015</year>) <article-title>Plug-and-play genetic access to drosophila cell types using exchangeable exon cassettes</article-title>. <source>Cell Rep</source> <volume>10</volume>:<fpage>1410</fpage>–<lpage>1421</lpage></mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diao</surname> <given-names>F</given-names></string-name>, <string-name><surname>White</surname> <given-names>BH</given-names></string-name></person-group> (<year>2012</year>) <article-title>A novel approach for directing transgene expression in Drosophila: T2A-Gal4 in-frame fusion</article-title>. <source>Genetics</source> <volume>190</volume>:<fpage>1139</fpage>–<lpage>1144</lpage></mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Donnelly</surname> <given-names>MLL</given-names></string-name>, <string-name><surname>Luke</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mehrotra</surname> <given-names>A</given-names></string-name>, <string-name><surname>Li</surname> <given-names>X</given-names></string-name>, <string-name><surname>Hughes</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Gani</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ryan</surname> <given-names>MD</given-names></string-name></person-group> (<year>2001</year>) <article-title>Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’</article-title>. <source>J Gen Virol</source> <volume>82</volume>:<fpage>1013</fpage>–<lpage>1025</lpage></mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ellis</surname> <given-names>MV</given-names></string-name>, <string-name><surname>James</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Perisic</surname> <given-names>O</given-names></string-name>, <string-name><surname>Downes</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Katan</surname> <given-names>M</given-names></string-name></person-group> (<year>1998</year>) <article-title>Catalytic domain of phosphoinositide-specific phospholipase C (PLC). Mutational analysis of residues within the active site and hydrophobic ridge of plcdelta1</article-title>. <source>J Biol Chem</source> <volume>273</volume>:<fpage>11650</fpage>-<lpage>11659</lpage></mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Exton</surname> <given-names>JH</given-names></string-name></person-group> (<year>1996</year>) <article-title>Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins</article-title>. <source>Annu Rev Pharmacol Toxicol</source> <volume>36</volume>:<fpage>481</fpage>–<lpage>509</lpage></mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Foskett</surname> <given-names>JK</given-names></string-name>, <string-name><surname>White</surname> <given-names>C</given-names></string-name>, <string-name><surname>Cheung</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Mak</surname> <given-names>DO</given-names></string-name></person-group> (<year>2007</year>) <article-title>Inositol trisphosphate receptor Ca2+ release channels</article-title>. <source>Physiol Rev</source> <volume>87</volume>:<fpage>593</fpage>–<lpage>658</lpage></mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gomes</surname> <given-names>DA</given-names></string-name>, <string-name><surname>de Miranda</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Faria</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rodrigues</surname> <given-names>MA</given-names></string-name></person-group> (<year>2021</year>) <article-title>The basis of nuclear phospholipase C in cell proliferation</article-title>. <source>Adv Biol Regul</source> <volume>82</volume>:<fpage>100834</fpage></mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gresset</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hicks</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Harden</surname> <given-names>TK</given-names></string-name>, <string-name><surname>Sondek</surname> <given-names>J</given-names></string-name></person-group> (<year>2010</year>) <article-title>Mechanism of phosphorylation-induced activation of phospholipase C-gamma isozymes</article-title>. <source>J Biol Chem</source> <volume>285</volume>:<fpage>35836</fpage>–<lpage>35847</lpage></mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gresset</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sondek</surname> <given-names>J</given-names></string-name>, <string-name><surname>Harden</surname> <given-names>TK</given-names></string-name></person-group> (<year>2012</year>) <article-title>The phospholipase C isozymes and their regulation</article-title>. <source>Subcell Biochem</source> <volume>58</volume>:<fpage>61</fpage>–<lpage>94</lpage></mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hajicek</surname> <given-names>N</given-names></string-name>, <string-name><surname>Charpentier</surname> <given-names>TH</given-names></string-name>, <string-name><surname>Rush</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Harden</surname> <given-names>TK</given-names></string-name>, <string-name><surname>Sondek</surname> <given-names>J</given-names></string-name></person-group> (<year>2013</year>) <article-title>Autoinhibition and phosphorylation-induced activation of phospholipase C-gamma isozymes</article-title>. <source>Biochemistry</source> <volume>52</volume>:<fpage>4810</fpage>–<lpage>4819</lpage></mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hajicek</surname> <given-names>N</given-names></string-name>, <string-name><surname>Keith</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Siraliev-Perez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Temple</surname> <given-names>BR</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Harden</surname> <given-names>TK</given-names></string-name>, <string-name><surname>Sondek</surname> <given-names>J</given-names></string-name></person-group> (<year>2019</year>) <article-title>Structural basis for the activation of PLC-gamma isozymes by phosphorylation and cancer-associated mutations</article-title>. <source>eLife</source> <elocation-id>8</elocation-id></mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hilgemann</surname> <given-names>DW</given-names></string-name></person-group> (<year>2007</year>) <article-title>Local PIP(2) signals: when, where, and how?</article-title> <source>Pflugers Arch</source> <volume>455</volume>:<fpage>55</fpage>–<lpage>67</lpage></mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hilgemann</surname> <given-names>DW</given-names></string-name>, <string-name><surname>Feng</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nasuhoglu</surname> <given-names>C</given-names></string-name></person-group> (<year>2001</year>) <article-title>The complex and intriguing lives of PIP2 with ion channels and transporters</article-title>. <source>Sci STKE</source> <volume>2001</volume>:<fpage>re19</fpage></mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Homma</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Takenawa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Emori</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sorimachi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Suzuki</surname> <given-names>K</given-names></string-name></person-group> (<year>1989</year>) <article-title>Tissue- and cell type-specific expression of mRNAs for four types of inositol phospholipid-specific phospholipase C</article-title>. <source>Biochem Biophys Res Commun</source> <volume>164</volume>:<fpage>406</fpage>–<lpage>412</lpage></mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Comjean</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rodiger</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>V</given-names></string-name>, <string-name><surname>Zirin</surname> <given-names>J</given-names></string-name>, <string-name><surname>Perrimon</surname> <given-names>N</given-names></string-name>, <string-name><surname>Mohr</surname> <given-names>SE</given-names></string-name></person-group> (<year>2021</year>) <article-title>FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2021 update</article-title>. <source>Nucleic Acids Res</source> <volume>49</volume>:<fpage>D908</fpage>-<lpage>D915</lpage></mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Lemire</surname> <given-names>G</given-names></string-name>, <string-name><surname>Briere</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wessels</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Osmond</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kanca</surname> <given-names>O</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>High</surname> <given-names>FA</given-names></string-name>, <string-name><surname>Walker</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Rodan</surname> <given-names>LH</given-names></string-name>, <string-name><surname>Undiagnosed Diseases</surname> <given-names>N</given-names></string-name>, <collab>Care4Rare Canada C</collab>, <string-name><surname>Kernohan</surname> <given-names>KD</given-names></string-name>, <string-name><surname>Sweetser</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Boycott</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name></person-group> (<year>2022a</year>) <article-title>The recurrent de novo c.2011C&gt;T missense variant in MTSS2 causes syndromic intellectual disability</article-title>. <source>Am J Hum Genet</source> <volume>109</volume>:<fpage>1923</fpage>-<lpage>1931</lpage></mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Pehlivan</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kanca</surname> <given-names>O</given-names></string-name>, <string-name><surname>Un-Candan</surname> <given-names>F</given-names></string-name>, <string-name><surname>Shu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Akay</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mitani</surname> <given-names>T</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Candan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Xiao</surname> <given-names>B</given-names></string-name>, <string-name><surname>Lupski</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name></person-group> (<year>2022b</year>) <article-title>Novel dominant and recessive variants in human ROBO1 cause distinct neurodevelopmental defects through different mechanisms</article-title>. <source>Hum Mol Genet</source> <volume>31</volume>:<fpage>2751</fpage>–<lpage>2765</lpage></mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ji</surname> <given-names>QS</given-names></string-name>, <string-name><surname>Winnier</surname> <given-names>GE</given-names></string-name>, <string-name><surname>Niswender</surname> <given-names>KD</given-names></string-name>, <string-name><surname>Horstman</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wisdom</surname> <given-names>R</given-names></string-name>, <string-name><surname>Magnuson</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Carpenter</surname> <given-names>G</given-names></string-name></person-group> (<year>1997</year>) <article-title>Essential role of the tyrosine kinase substrate phospholipase C-gamma1 in mammalian growth and development</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>94</volume>:<fpage>2999</fpage>–<lpage>3003</lpage></mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kadamur</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>EM</given-names></string-name></person-group> (<year>2013</year>) <article-title>Mammalian phospholipase C</article-title>. <source>Annu Rev Physiol</source> <volume>75</volume>:<fpage>127</fpage>–<lpage>154</lpage></mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karczewski</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Francioli</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Tiao</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cummings</surname> <given-names>BB</given-names></string-name>, <string-name><surname>Alfoldi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Collins</surname> <given-names>RL</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2020</year>) <article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title>. <source>Nature</source> <volume>581</volume>:<fpage>434</fpage>–<lpage>443</lpage></mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Katan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cockcroft</surname> <given-names>S</given-names></string-name></person-group> (<year>2020</year>) <article-title>Phospholipase C families: Common themes and versatility in physiology and pathology</article-title>. <source>Prog Lipid Res</source> <volume>80</volume>:<fpage>101065</fpage></mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kataoka</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nagata</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kitanaka</surname> <given-names>A</given-names></string-name>, <string-name><surname>Shiraishi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Shimamura</surname> <given-names>T</given-names></string-name>, <string-name><surname>Yasunaga</surname> <given-names>J</given-names></string-name>, <string-name><surname>Totoki</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Integrated molecular analysis of adult T cell leukemia/lymphoma</article-title>. <source>Nat Genet</source> <volume>47</volume>:<fpage>1304</fpage>–<lpage>1315</lpage></mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kunze</surname> <given-names>K</given-names></string-name>, <string-name><surname>Spieker</surname> <given-names>T</given-names></string-name>, <string-name><surname>Gamerdinger</surname> <given-names>U</given-names></string-name>, <string-name><surname>Nau</surname> <given-names>K</given-names></string-name>, <string-name><surname>Berger</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dreyer</surname> <given-names>T</given-names></string-name>, <string-name><surname>Sindermann</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Hoffmeier</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gattenlohner</surname> <given-names>S</given-names></string-name>, <string-name><surname>Brauninger</surname> <given-names>A</given-names></string-name></person-group> (<year>2014</year>) <article-title>A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells</article-title>. <source>Cancer Res</source> <volume>74</volume>:<fpage>6173</fpage>–<lpage>6183</lpage></mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Le Huray</surname> <given-names>KIP</given-names></string-name>, <string-name><surname>Bunney</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Pinotsis</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kalli</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Katan</surname> <given-names>M</given-names></string-name></person-group> (<year>2022</year>) <article-title>Characterization of the membrane interactions of phospholipase Cgamma reveals key features of the active enzyme</article-title>. <source>Sci Adv</source> <volume>8</volume>:<fpage>eabp9688</fpage></mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname> <given-names>PT</given-names></string-name>, <string-name><surname>Zirin</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kanca</surname> <given-names>O</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>WW</given-names></string-name>, <string-name><surname>Schulze</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Li-Kroeger</surname> <given-names>D</given-names></string-name>, <string-name><surname>Tao</surname> <given-names>R</given-names></string-name>, <string-name><surname>Devereaux</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>V</given-names></string-name>, <string-name><surname>Fang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>He</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ge</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zuo</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Housden</surname> <given-names>BE</given-names></string-name>, <string-name><surname>Mohr</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Yamamoto</surname> <given-names>S</given-names></string-name>, <string-name><surname>Levis</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Spradling</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Perrimon</surname> <given-names>N</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name></person-group> (<year>2018</year>) <article-title>A gene-specific T2A-GAL4 library for Drosophila</article-title>. <source>eLife</source> <elocation-id>7</elocation-id></mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Karczewski</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Minikel</surname> <given-names>EV</given-names></string-name>, <string-name><surname>Samocha</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Banks</surname> <given-names>E</given-names></string-name>, <string-name><surname>Fennell</surname> <given-names>T</given-names></string-name>, <string-name><surname>O’Donnell-Luria</surname> <given-names>AH</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source>Nature</source> <volume>536</volume>:<fpage>285</fpage>–<lpage>291</lpage></mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liao</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Kume</surname> <given-names>T</given-names></string-name>, <string-name><surname>McKay</surname> <given-names>C</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Ihle</surname> <given-names>JN</given-names></string-name>, <string-name><surname>Carpenter</surname> <given-names>G</given-names></string-name></person-group> (<year>2002</year>) <article-title>Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice</article-title>. <source>J Biol Chem</source> <volume>277</volume>:<fpage>9335</fpage>–<lpage>9341</lpage></mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Bunney</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Khosa</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mace</surname> <given-names>K</given-names></string-name>, <string-name><surname>Beckenbauer</surname> <given-names>K</given-names></string-name>, <string-name><surname>Askwith</surname> <given-names>T</given-names></string-name>, <string-name><surname>Maslen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Stubbs</surname> <given-names>C</given-names></string-name>, <string-name><surname>de Oliveira</surname> <given-names>TM</given-names></string-name>, <string-name><surname>Sader</surname> <given-names>K</given-names></string-name>, <string-name><surname>Skehel</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gavin</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Phillips</surname> <given-names>C</given-names></string-name>, <string-name><surname>Katan</surname> <given-names>M</given-names></string-name></person-group> (<year>2020</year>) <article-title>Structural insights and activating mutations in diverse pathologies define mechanisms of deregulation for phospholipase C gamma enzymes</article-title>. <source>EBioMedicine</source> <volume>51</volume>:<fpage>102607</fpage></mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hernan</surname> <given-names>R</given-names></string-name>, <string-name><surname>Marcogliese</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Gertler</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Akcaboy</surname> <given-names>M</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>HL</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>X</given-names></string-name>, <string-name><surname>Oguz</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Oztoprak</surname> <given-names>U</given-names></string-name>, <string-name><surname>de Baaij</surname> <given-names>JHF</given-names></string-name>, <string-name><surname>Ivanisevic</surname> <given-names>J</given-names></string-name>, <string-name><surname>McGinnis</surname> <given-names>E</given-names></string-name>, <string-name><surname>Guillen Sacoto</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>WK</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name></person-group> (<year>2022a</year>) <article-title>Loss-of-function variants in TIAM1 are associated with developmental delay, intellectual disability, and seizures</article-title>. <source>Am J Hum Genet</source> <volume>109</volume>:<fpage>571</fpage>–<lpage>586</lpage></mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Bacino</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Jankovic</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sutton</surname> <given-names>VR</given-names></string-name>, <string-name><surname>Bartley</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Rosenfeld</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Beleza-Meireles</surname> <given-names>A</given-names></string-name>, <string-name><surname>Chauhan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Li</surname> <given-names>M</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Prescott</surname> <given-names>K</given-names></string-name>, <string-name><surname>Amin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Davies</surname> <given-names>G</given-names></string-name>, <string-name><surname>Wangler</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Dai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name></person-group> (<year>2022b</year>) <article-title>De novo variants in FRMD5 are associated with developmental delay, intellectual disability, ataxia, and abnormalities of eye movement</article-title>. <source>Am J Hum Genet</source> <volume>109</volume>:<fpage>1932</fpage>–<lpage>1943</lpage></mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zheng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Mao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>HL</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name></person-group> (<year>2023</year>) <article-title>The fly homolog of SUPT16H, a gene associated with neurodevelopmental disorders, is required in a cell-autonomous fashion for cell survival</article-title>. <source>Hum Mol Genet</source> <volume>32</volume>:<fpage>984</fpage>–<lpage>997</lpage></mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Majerus</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Connolly</surname> <given-names>TM</given-names></string-name>, <string-name><surname>Deckmyn</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Bross</surname> <given-names>TE</given-names></string-name>, <string-name><surname>Ishii</surname> <given-names>H</given-names></string-name>, <string-name><surname>Bansal</surname> <given-names>VS</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>DB</given-names></string-name></person-group> (<year>1986</year>) <article-title>The metabolism of phosphoinositide-derived messenger molecules</article-title>. <source>Science</source> <volume>234</volume>:<fpage>1519</fpage>–<lpage>1526</lpage></mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Manso</surname> <given-names>R</given-names></string-name>, <string-name><surname>Rodriguez-Pinilla</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Gonzalez-Rincon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gomez</surname> <given-names>S</given-names></string-name>, <string-name><surname>Monsalvo</surname> <given-names>S</given-names></string-name>, <string-name><surname>Llamas</surname> <given-names>P</given-names></string-name>, <string-name><surname>Rojo</surname> <given-names>F</given-names></string-name>, <string-name><surname>Perez-Callejo</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cereceda</surname> <given-names>L</given-names></string-name>, <string-name><surname>Limeres</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Maeso</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ferrando</surname> <given-names>L</given-names></string-name>, <string-name><surname>Perez-Seoane</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rodriguez</surname> <given-names>G</given-names></string-name>, <string-name><surname>Arrinda</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Garcia-Bragado</surname> <given-names>F</given-names></string-name>, <string-name><surname>Franco</surname> <given-names>R</given-names></string-name>, <string-name><surname>Rodriguez-Peralto</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Gonzalez-Carrero</surname> <given-names>J</given-names></string-name>, <string-name><surname>Martin-Davila</surname> <given-names>F</given-names></string-name>, <string-name><surname>Piris</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Sanchez-Beato</surname> <given-names>M</given-names></string-name></person-group> (<year>2015</year>) <article-title>Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas</article-title>. <source>Haematologica</source> <volume>100</volume>:<fpage>e25</fpage>–<lpage>27</lpage></mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Masuyama</surname> <given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Rao</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>JW</given-names></string-name></person-group> (<year>2012</year>) <article-title>Mapping neural circuits with activity-dependent nuclear import of a transcription factor</article-title>. <source>J Neurogenet</source> <volume>26</volume>:<fpage>89</fpage>–<lpage>102</lpage></mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neves</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Doffinger</surname> <given-names>R</given-names></string-name>, <string-name><surname>Barcena-Morales</surname> <given-names>G</given-names></string-name>, <string-name><surname>Martins</surname> <given-names>C</given-names></string-name>, <string-name><surname>Papapietro</surname> <given-names>O</given-names></string-name>, <string-name><surname>Plagnol</surname> <given-names>V</given-names></string-name>, <string-name><surname>Curtis</surname> <given-names>J</given-names></string-name>, <string-name><surname>Martins</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kumararatne</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cordeiro</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Neves</surname> <given-names>C</given-names></string-name>, <string-name><surname>Borrego</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Katan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Nejentsev</surname> <given-names>S</given-names></string-name></person-group> (<year>2018</year>) <article-title>Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa</article-title>. <source>Front Immunol</source> <volume>9</volume>:<fpage>2863</fpage></mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nishizuka</surname> <given-names>Y</given-names></string-name></person-group> (<year>1984</year>) <article-title>Turnover of inositol phospholipids and signal transduction</article-title>. <source>Science</source> <volume>225</volume>:<fpage>1365</fpage>–<lpage>1370</lpage></mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nishizuka</surname> <given-names>Y</given-names></string-name></person-group> (<year>1992</year>) <article-title>Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C</article-title>. <source>Science</source> <volume>258</volume>:<fpage>607</fpage>–<lpage>614</lpage></mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noh</surname> <given-names>DY</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>YH</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>YI</given-names></string-name>, <string-name><surname>Ryu</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Suh</surname> <given-names>PG</given-names></string-name>, <string-name><surname>Park</surname> <given-names>JG</given-names></string-name></person-group> (<year>1994</year>) <article-title>Elevated content of phospholipase C-gamma 1 in colorectal cancer tissues</article-title>. <source>Cancer</source> <volume>73</volume>:<fpage>36</fpage>–<lpage>41</lpage></mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nosbisch</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Bear</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Haugh</surname> <given-names>JM</given-names></string-name></person-group> (<year>2022</year>) <article-title>A kinetic model of phospholipase C-gamma1 linking structure-based insights to dynamics of enzyme autoinhibition and activation</article-title>. <source>J Biol Chem</source> <volume>298</volume>:<fpage>101886</fpage></mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ombrello</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Remmers</surname> <given-names>EF</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>G</given-names></string-name>, <string-name><surname>Freeman</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Datta</surname> <given-names>S</given-names></string-name>, <string-name><surname>Torabi-Parizi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Subramanian</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions</article-title>. <source>N Engl J Med</source> <volume>366</volume>:<fpage>330</fpage>–<lpage>338</lpage></mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Pan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Alvarez</surname> <given-names>AN</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Crawford</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Briere</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Kanca</surname> <given-names>O</given-names></string-name>, <string-name><surname>Yamamoto</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sweetser</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Napier</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Pruneda</surname> <given-names>JN</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name></person-group> (<year>2023</year>) <article-title>Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays</article-title>. <source>medRxiv</source></mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>YH</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Park</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Noh</surname> <given-names>DY</given-names></string-name>, <string-name><surname>Ryu</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Suh</surname> <given-names>PG</given-names></string-name></person-group> (<year>1994</year>) <article-title>Overexpression of phospholipase C-gamma 1 in familial adenomatous polyposis</article-title>. <source>Cancer Res</source> <volume>54</volume>:<fpage>2240</fpage>–<lpage>2244</lpage></mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pettersen</surname> <given-names>EF</given-names></string-name>, <string-name><surname>Goddard</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Couch</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Greenblatt</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Meng</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Ferrin</surname> <given-names>TE</given-names></string-name></person-group> (<year>2004</year>) <article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title>. <source>J Comput Chem</source> <volume>25</volume>:<fpage>1605</fpage>–<lpage>1612</lpage></mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quinodoz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Royer-Bertrand</surname> <given-names>B</given-names></string-name>, <string-name><surname>Cisarova</surname> <given-names>K</given-names></string-name>, <string-name><surname>Di Gioia</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Superti-Furga</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rivolta</surname> <given-names>C</given-names></string-name></person-group> (<year>2017</year>) <article-title>DOMINO: Using Machine Learning to Predict Genes Associated with Dominant Disorders</article-title>. <source>Am J Hum Genet</source> <volume>101</volume>:<fpage>623</fpage>–<lpage>629</lpage></mixed-citation></ref>
<ref id="c58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Regunathan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kutlesa</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dai</surname> <given-names>X</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wen</surname> <given-names>R</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Malarkannan</surname> <given-names>S</given-names></string-name></person-group> (<year>2006</year>) <article-title>Differential and nonredundant roles of phospholipase Cgamma2 and phospholipase Cgamma1 in the terminal maturation of NK cells</article-title>. <source>J Immunol</source> <volume>177</volume>:<fpage>5365</fpage>–<lpage>5376</lpage></mixed-citation></ref>
<ref id="c59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reinius</surname> <given-names>B</given-names></string-name>, <string-name><surname>Sandberg</surname> <given-names>R</given-names></string-name></person-group> (<year>2015</year>) <article-title>Random monoallelic expression of autosomal genes: stochastic transcription and allele-level regulation</article-title>. <source>Nat Rev Genet</source> <volume>16</volume>:<fpage>653</fpage>–<lpage>664</lpage></mixed-citation></ref>
<ref id="c60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robinow</surname> <given-names>S</given-names></string-name>, <string-name><surname>White</surname> <given-names>K</given-names></string-name></person-group> (<year>1991</year>) <article-title>Characterization and spatial distribution of the ELAV protein during Drosophila melanogaster development</article-title>. <source>J Neurobiol</source> <volume>22</volume>:<fpage>443</fpage>–<lpage>461</lpage></mixed-citation></ref>
<ref id="c61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sepp</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Schulte</surname> <given-names>J</given-names></string-name>, <string-name><surname>Auld</surname> <given-names>VJ</given-names></string-name></person-group> (<year>2001</year>) <article-title>Peripheral glia direct axon guidance across the CNS/PNS transition zone</article-title>. <source>Dev Biol</source> <volume>238</volume>:<fpage>47</fpage>–<lpage>63</lpage></mixed-citation></ref>
<ref id="c62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siraliev-Perez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Stariha</surname> <given-names>JTB</given-names></string-name>, <string-name><surname>Hoffmann</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Temple</surname> <given-names>BRS</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Hajicek</surname> <given-names>N</given-names></string-name>, <string-name><surname>Jenkins</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Burke</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Sondek</surname> <given-names>J</given-names></string-name></person-group> (<year>2022</year>) <article-title>Dynamics of allosteric regulation of the phospholipase C-gamma isozymes upon recruitment to membranes</article-title>. <source>eLife</source> <elocation-id>11</elocation-id></mixed-citation></ref>
<ref id="c63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>YL</given-names></string-name>, <string-name><surname>Matthews</surname> <given-names>NT</given-names></string-name>, <string-name><surname>Rhee</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Sung</surname> <given-names>WK</given-names></string-name>, <string-name><surname>Kung</surname> <given-names>HF</given-names></string-name></person-group> (<year>1994</year>) <article-title>Phospholipase C-gamma 1 can induce DNA synthesis by a mechanism independent of its lipase activity</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>91</volume>:<fpage>6554</fpage>–<lpage>6558</lpage></mixed-citation></ref>
<ref id="c64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sobreira</surname> <given-names>N</given-names></string-name>, <string-name><surname>Schiettecatte</surname> <given-names>F</given-names></string-name>, <string-name><surname>Valle</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hamosh</surname> <given-names>A</given-names></string-name></person-group> (<year>2015</year>) <article-title>GeneMatcher: a matching tool for connecting investigators with an interest in the same gene</article-title>. <source>Hum Mutat</source> <volume>36</volume>:<fpage>928</fpage>–<lpage>930</lpage></mixed-citation></ref>
<ref id="c65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Splinter</surname> <given-names>K</given-names></string-name>, <string-name><surname>Adams</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Bacino</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Bernstein</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Cheatle-Jarvela</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Eng</surname> <given-names>CM</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease</article-title>. <source>N Engl J Med</source> <volume>379</volume>:<fpage>2131</fpage>–<lpage>2139</lpage></mixed-citation></ref>
<ref id="c66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Suh</surname> <given-names>BC</given-names></string-name>, <string-name><surname>Hille</surname> <given-names>B</given-names></string-name></person-group> (<year>2008</year>) <article-title>PIP2 is a necessary cofactor for ion channel function: how and why?</article-title> <source>Annu Rev Biophys</source> <volume>37</volume>:<fpage>175</fpage>–<lpage>195</lpage></mixed-citation></ref>
<ref id="c67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Suh</surname> <given-names>PG</given-names></string-name>, <string-name><surname>Park</surname> <given-names>JI</given-names></string-name>, <string-name><surname>Manzoli</surname> <given-names>L</given-names></string-name>, <string-name><surname>Cocco</surname> <given-names>L</given-names></string-name>, <string-name><surname>Peak</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Katan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fukami</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kataoka</surname> <given-names>T</given-names></string-name>, <string-name><surname>Yun</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ryu</surname> <given-names>SH</given-names></string-name></person-group> (<year>2008</year>) <article-title>Multiple roles of phosphoinositide-specific phospholipase C isozymes</article-title>. <source>BMB Rep</source> <volume>41</volume>:<fpage>415</fpage>–<lpage>434</lpage></mixed-citation></ref>
<ref id="c68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname> <given-names>KY</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>X</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bao</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kapoor</surname> <given-names>M</given-names></string-name>, <string-name><surname>Backman</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2024</year>) <article-title>A deep catalogue of protein-coding variation in 983,578 individuals</article-title>. <source>Nature</source> <volume>631</volume>:<fpage>583</fpage>–<lpage>592</lpage></mixed-citation></ref>
<ref id="c69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tao</surname> <given-names>P</given-names></string-name>, <string-name><surname>Han</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>L</given-names></string-name>, <string-name><surname>Fan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>PY</given-names></string-name>, <string-name><surname>Aksentijevich</surname> <given-names>I</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Q</given-names></string-name></person-group> (<year>2023</year>) <article-title>A gain-of-function variation in PLCG1 causes a new immune dysregulation disease</article-title>. <source>J Allergy Clin Immunol</source> <volume>152</volume>:<fpage>1292</fpage>–<lpage>1302</lpage></mixed-citation></ref>
<ref id="c70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thackeray</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Gaines</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Ebert</surname> <given-names>P</given-names></string-name>, <string-name><surname>Carlson</surname> <given-names>JR</given-names></string-name></person-group> (<year>1998</year>) <article-title>small wing encodes a phospholipase C-(gamma) that acts as a negative regulator of R7 development in Drosophila</article-title>. <source>Development</source> <volume>125</volume>:<fpage>5033</fpage>–<lpage>5042</lpage></mixed-citation></ref>
<ref id="c71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trivedi</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cm</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bisht</surname> <given-names>K</given-names></string-name>, <string-name><surname>Janardan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Pandit</surname> <given-names>A</given-names></string-name>, <string-name><surname>Basak B</surname>, <given-names>H S</given-names></string-name>, <string-name><surname>Ramesh</surname> <given-names>N</given-names></string-name>, <string-name><surname>Raghu</surname> <given-names>P</given-names></string-name></person-group> (<year>2020</year>) <article-title>A genome engineering resource to uncover principles of cellular organization and tissue architecture by lipid signaling</article-title>. <source>eLife</source> <volume>9</volume></mixed-citation></ref>
<ref id="c72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaque</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Gomez-Lopez</surname> <given-names>G</given-names></string-name>, <string-name><surname>Monsalvez</surname> <given-names>V</given-names></string-name>, <string-name><surname>Varela</surname> <given-names>I</given-names></string-name>, <string-name><surname>Martinez</surname> <given-names>N</given-names></string-name>, <string-name><surname>Perez</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dominguez</surname> <given-names>O</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2014</year>) <article-title>PLCG1 mutations in cutaneous T-cell lymphomas</article-title>. <source>Blood</source> <volume>123</volume>:<fpage>2034</fpage>–<lpage>2043</lpage></mixed-citation></ref>
<ref id="c73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Venken</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Popodi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Holtzman</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Schulze</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Park</surname> <given-names>S</given-names></string-name>, <string-name><surname>Carlson</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Hoskins</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Kaufman</surname> <given-names>TC</given-names></string-name></person-group> (<year>2010</year>) <article-title>A molecularly defined duplication set for the X chromosome of Drosophila melanogaster</article-title>. <source>Genetics</source> <volume>186</volume>:<fpage>1111</fpage>–<lpage>1125</lpage></mixed-citation></ref>
<ref id="c74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wada</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rathnayake</surname> <given-names>U</given-names></string-name>, <string-name><surname>Jenkins</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mohammadi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Appella</surname> <given-names>E</given-names></string-name>, <string-name><surname>Randazzo</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Samelson</surname> <given-names>LE</given-names></string-name></person-group> (<year>2022</year>) <article-title>In vitro reconstitution reveals cooperative mechanisms of adapter protein-mediated activation of phospholipase C-gamma1 in T cells</article-title>. <source>J Biol Chem</source> <volume>298</volume>:<fpage>101680</fpage></mixed-citation></ref>
<ref id="c75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Al-Ouran</surname> <given-names>R</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Wan</surname> <given-names>YW</given-names></string-name>, <string-name><surname>Wangler</surname> <given-names>MF</given-names></string-name>, <string-name><surname>Yamamoto</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chao</surname> <given-names>HT</given-names></string-name>, <string-name><surname>Comjean</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mohr</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Udn</surname>, <given-names>Perrimon N</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Bellen</surname> <given-names>HJ</given-names></string-name></person-group> (<year>2017</year>) <article-title>MARRVEL: Integration of Human and Model Organism Genetic Resources to Facilitate Functional Annotation of the Human Genome</article-title>. <source>Am J Hum Genet</source> <volume>100</volume>:<fpage>843</fpage>–<lpage>853</lpage></mixed-citation></ref>
<ref id="c76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liao</surname> <given-names>EY</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>FY</given-names></string-name>, <string-name><surname>Pennypacker</surname> <given-names>SD</given-names></string-name></person-group> (<year>2010</year>) <article-title>Phospholipase C-gamma1 is required for the epidermal growth factor receptor-induced squamous cell carcinoma cell mitogenesis</article-title>. <source>Biochem Biophys Res Commun</source> <volume>397</volume>:<fpage>296</fpage>-<lpage>300</lpage></mixed-citation></ref>
<ref id="c77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>YR</given-names></string-name>, <string-name><surname>Choi</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Chang</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Kwon</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Jang</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Ryu</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Suh</surname> <given-names>PG</given-names></string-name></person-group> (<year>2012</year>) <article-title>Diverse cellular and physiological roles of phospholipase C-gamma1</article-title>. <source>Adv Biol Regul</source> <volume>52</volume>:<fpage>138</fpage>–<lpage>151</lpage></mixed-citation></ref>
<ref id="c78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Constien</surname> <given-names>R</given-names></string-name>, <string-name><surname>Dear</surname> <given-names>N</given-names></string-name>, <string-name><surname>Katan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hanke</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bunney</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Kunder</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2005</year>) <article-title>Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C gamma 2 that specifically increases external Ca2+ entry</article-title>. <source>Immunity</source> <volume>22</volume>:<fpage>451</fpage>–<lpage>465</lpage></mixed-citation></ref>
<ref id="c79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Brady</surname> <given-names>J</given-names></string-name>, <string-name><surname>Datta</surname> <given-names>S</given-names></string-name>, <string-name><surname>Katan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sheikh</surname> <given-names>A</given-names></string-name>, <string-name><surname>Martins</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Bunney</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Santich</surname> <given-names>BH</given-names></string-name>, <string-name><surname>Moir</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kuhns</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Long Priel</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Ombrello</surname> <given-names>A</given-names></string-name>, <string-name><surname>Stone</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ombrello</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Khan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Milner</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Kastner</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Aksentijevich</surname> <given-names>I</given-names></string-name></person-group> (<year>2012</year>) <article-title>A hypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency</article-title>. <source>Am J Hum Genet</source> <volume>91</volume>:<fpage>713</fpage>–<lpage>720</lpage></mixed-citation></ref>
<ref id="c80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Pires</surname> <given-names>DEV</given-names></string-name>, <string-name><surname>Rodrigues</surname> <given-names>CHM</given-names></string-name>, <string-name><surname>Ascher</surname> <given-names>DB</given-names></string-name></person-group> (<year>2023</year>) <article-title>DDMut: predicting effects of mutations on protein stability using deep learning</article-title>. <source>Nucleic Acids Res</source> <volume>51</volume>:<fpage>W122</fpage>–<lpage>W128</lpage></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.95887.2.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nahmad</surname>
<given-names>Marcos</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Center for Research and Advanced Studies of the National Polytechnic Institute</institution>
</institution-wrap>
<city>Mexico City</city>
<country>Mexico</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Compelling</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>important</bold> study reveals how Drosophila may be used to investigate the role of missense variants in the PLCG1 phospholipase gene in human diseases. The experimental evidence is <bold>compelling</bold> and brings together rigorous analysis of clinical and model organism phenotypes with a structural analysis of the PLCG1 protein.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.95887.2.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The manuscript by Ma et al. reports the identification of three unrelated people who are heterozygous for de novo missense variants in PLCG1, which encodes phospholipase C-gamma 1, a key signaling protein. These individuals present with partially overlapping phenotypes, including hearing loss, ocular pathology, cardiac defects, abnormal brain imaging results, and immune defects. None of the patients present with all of the above phenotypes. PLCG1 has also been implicated as a possible driver for cell proliferation in cancer.</p>
<p>The three missense variants found in the patients result in the following amino acid substitutions: His380Arg, Asp1019Gly, and Asp1165Gly. PLCG1 (and the closely related PLCG2) have a single Drosophila ortholog called small wing (sl). sl-null flies are viable but have small wings with ectopic wing veins and supernumerary photoreceptors in the eye. As all three amino acids affected in the patients are conserved in the fly protein, in this work Ma et al. tested whether they are pathogenic by expressing either reference or patient variant fly or human genes in Drosophila and determining the phenotypes produced by doing so.</p>
<p>Expression in Drosophila of the variant forms of PLCG1 found in these three patients is toxic; highly so for Asp1019Gly and Asp1165Gly, much more modestly for His380Arg. Another variant, Asp1165His which was identified in lymphoma samples and shown by others to be hyperactive, was also found to be toxic in the Drosophila assays. However, a final variant, Ser1021Phe, identified by others in an individual with severe immune dysregulation, produced no phenotype upon expression in flies.</p>
<p>Based on these results, the authors conclude that the PLCG1 variants found in patients are pathogenic, producing gain-of-function phenotypes through hyperactivity. In my view, the data supporting this conclusion are robust, despite the lack of a detectable phenotype with Ser1021Phe, and I have no concerns about the core experiments that comprise the paper.</p>
<p>Fig. 6, the last in the paper, provides information about PLCG1 structure and how the different variants would affect it. It shows that His380, Asp1019 and Asp1165 all lie within catalytic domains or intramolecular interfaces, and that variants in the latter two affect residues essential for autoinhibition. It also shows that Ser1021 falls outside the key interface occupied by Asp1019, but more could have been said about the potential effects of Ser1021Phe.</p>
<p>Overall, I believe the authors fully achieved the aims of their study. The work will have a substantial impact because it reports the identification of novel disease-linked genes, and because it further demonstrates the high value of the Drosophila model for finding and understanding gene-disease linkages.</p>
<p>Comments on revisions:</p>
<p>The single recommendation I made on the original version, which was to further examine H380 mutants, has been satisfactorily addressed in the revised version.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.95887.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Mengqi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Yiming</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deng</surname>
<given-names>Mingxi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Shenzhao</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pan</surname>
<given-names>Xueyang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luo</surname>
<given-names>Xi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Etoundi</surname>
<given-names>Michelle</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li-Kroeger</surname>
<given-names>David</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Worley</surname>
<given-names>Kim C</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burrage</surname>
<given-names>Lindsay C</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blieden</surname>
<given-names>Lauren S</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Allworth</surname>
<given-names>Aimee</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Wei-Liang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Merla</surname>
<given-names>Giuseppe</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mandriani</surname>
<given-names>Barbara</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Otten</surname>
<given-names>Catherine E</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blanc</surname>
<given-names>Pierre</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosenfeld</surname>
<given-names>Jill A</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dutta</surname>
<given-names>Debdeep</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>Shinya</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2172-8036</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Wangler</surname>
<given-names>Michael F</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<collab>Undiagnosed Diseases Network</collab>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Glass</surname>
<given-names>Ian A</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Jingheng</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blue</surname>
<given-names>Elizabeth</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0633-0305</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Prontera</surname>
<given-names>Paolo</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosain</surname>
<given-names>Jeremie</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marlin</surname>
<given-names>Sandrine</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lalani</surname>
<given-names>Seema R</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bellen</surname>
<given-names>Hugo J</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public Review):</bold></p>
<p>Summary:</p>
<p>This manuscript provides an initial characterization of three new missense variants of the PLCG1 gene associated with diverse disease phenotypes, utilizing a Drosophila model to investigate their molecular effects in vivo. Through the meticulous creation of genetic tools, the study assesses the small wing (sl) phenotype - the fly's ortholog of PLCG1 - across an array of phenotypes from longevity to behavior in both sl null mutants and variants. The findings indicate that the Drosophila PLCG1 ortholog displays aberrant functions. Notably, it is demonstrated that overexpression of both human and Drosophila PLCG1 variants in fly tissue leads to toxicity, underscoring their pathogenic potential in vivo.</p>
<p>Strengths:</p>
<p>The research effectively highlights the physiological significance of sl in Drosophila. In addition, the study establishes the in vivo toxicity of disease-associated variants of both human PLCG1 and Drosophila sl.</p>
<p>Weaknesses:</p>
<p>The study's limitations include the human PLCG1 transgene's inability to compensate for the Drosophila sl null mutant phenotype, suggesting potential functional divergence between the species. This discrepancy signals the need for additional exploration into the mechanistic nuances of PLCG1 variant pathogenesis, especially regarding their gain-of-function effects in vivo.</p>
<p>Overall:</p>
<p>The study offers compelling evidence for the pathogenicity of newly discovered disease-related PLCG1 variants, manifesting as toxicity in a Drosophila in vivo model, which substantiates the main claim by the authors. Nevertheless, a deeper inquiry into the specific in vivo mechanisms driving the toxicity caused by these variants in Drosophila could significantly enhance the study's impact.</p>
<p><bold>Reviewer #2 (Public Review):</bold></p>
<p>The manuscript by Ma et al. reports the identification of three unrelated people who are heterozygous for de novo missense variants in PLCG1, which encodes phospholipase C-gamma 1, a key signaling protein. These individuals present with partially overlapping phenotypes including hearing loss, ocular pathology, cardiac defects, abnormal brain imaging results, and immune defects. None of the patients present with all of the above phenotypes. PLCG1 has also been implicated as a possible driver for cell proliferation in cancer.</p>
<p>The three missense variants found in the patients result in the following amino acid substitutions: His380Arg, Asp1019Gly, and Asp1165Gly. PLCG1 (and the closely related PLCG2) have a single Drosophila ortholog called small wing (sl). sl-null flies are viable but have small wings with ectopic wing veins and supernumerary photoreceptors in the eye. As all three amino acids affected in the patients are conserved in the fly protein, in this work Ma et al. tested whether they are pathogenic by expressing either reference or patient variant fly or human genes in Drosophila and determining the phenotypes produced by doing so.</p>
<p>Expression in Drosophila of the variant forms of PLCG1 found in these three patients is toxic; highly so for Asp1019Gly and Asp1165Gly, much more modestly for His380Arg. Another variant, Asp1165His which was identified in lymphoma samples and shown by others to be hyperactive, was also found to be toxic in the Drosophila assays. However, a final variant, Ser1021Phe, identified by others in an individual with severe immune dysregulation, produced no phenotype upon expression in flies.</p>
<p>Based on these results, the authors conclude that the PLCG1 variants found in patients are pathogenic, producing gain-of-function phenotypes through hyperactivity. In my view, the data supporting this conclusion are robust, despite the lack of a detectable phenotype with Ser1021Phe, and I have no concerns about the core experiments that comprise the paper.</p>
<p>Figure 6, the last in the paper, provides information about PLCG1 structure and how the different variants would affect it. It shows that the His380, Asp1019, and Asp1165 all lie within catalytic domains or intramolecular interfaces and that variants in the latter two affect residues essential for autoinhibition. It also shows that Ser1021 falls outside the key interface occupied by Asp1019, but more could have been said about the potential effects of Ser1021Phe.</p>
<p>Overall, I believe the authors fully achieved the aims of their study. The work will have a substantial impact because it reports the identification of novel disease-linked genes, and because it further demonstrates the high value of the Drosophila model for finding and understanding gene-disease linkages.</p>
<p><bold>Reviewer #3 (Public Review):</bold></p>
<p>Summary:</p>
<p>The paper attempts to model the functional significance of variants of PLCG2 in a set of patients with variable clinical manifestations.</p>
<p>Strengths:</p>
<p>A study attempting to use the Drosophila system to test the function of variants reported from human patients.</p>
<p>Weaknesses:</p>
<p>Additional experiments are needed to shore up the claims in the paper. These are listed below.</p>
<p>Major Comments:</p>
<p>(1) Does the pLI/ missense constraint Z score prediction algorithm take into consideration whether the gene exhibits monoallelic or biallelic expression?</p>
</disp-quote>
<p>To our knowledge, pLI and missense Z don't consider monoallelic or biallelic expression. Instead, they reflect sequence constraint and are calculated based on the observed versus expected variant frequencies in population databases.</p>
<disp-quote content-type="editor-comment">
<p>(2) Figure 1B: Include human PLCG2 in the alignment that displays the species-wide conserved variant residues.</p>
</disp-quote>
<p>We have updated Figure 1B and incorporated the alignment of PLCG2.</p>
<disp-quote content-type="editor-comment">
<p>(3) Figure 4A:</p>
<p>Given that</p>
<p>(i) sl is predicted to be the fly ortholog for both mammalian PLCγ isozymes: PLCG1 and PLCG2 [Line 62]</p>
<p>(ii) they are shown to have non-redundant roles in mammals [Line 71]</p>
<p>(iii) reconstituting PLCG1 is highly toxic in flies, leading to increased lethality.</p>
<p>This raises questions about whether sl mutant phenotypes are specifically caused by the absence of PLCG1 or PLCG2 functions in flies. Can hPLCG2 reconstitution in sl mutants be used as a negative control to rule out the possibility of the same?</p>
</disp-quote>
<p>The studies about the non-redundant roles of PLCG1 and PLCG2 mainly concern the immune system.</p>
<p>We have assessed the phenotypes in the <italic>sl<sup>T2A</sup>/Y; UAS-hPLCG2</italic> flies. Expression of human PLCG2 in flies is also toxic and leads to severely reduced eclosion rate.</p>
<p>We have updated the manuscript with these results, and included the eclosion rate of <italic>sl<sup>T2A</sup>/Y; UAS-hPLCG2</italic> flies in the new Figure 4B.</p>
<disp-quote content-type="editor-comment">
<p>(4) Do slT2A/Y; UAS-PLCG1Reference flies survive when grown at 22{degree sign}C? Since transgenic fly expressing PLCG1 cDNA when driven under ubiquitous gal4s, Tubulin and Da, can result in viable progeny at 22{degree sign}C, the survival of slT2A/Y; UAS-PLCG1Reference should be possible.</p>
</disp-quote>
<p>The eclosion rate of <italic>sl<sup>T2A</sup>/Y &gt;PLCG1<sup>Reference</sup></italic> flies at 22°C is slightly higher than at 25°C, but remains severely reduced compared to the UAS-Empty control. We have presented these results in the updated Figure S3.</p>
<disp-quote content-type="editor-comment">
<p>and similarly</p>
<p>Does slT2A flies exhibit the phenotypes of (i) reduced eclosion rate (ii) reduced wing size and ectopic wing veins and (iii) extra R7 photoreceptor in the fly eye at 22{degree sign}C?</p>
</disp-quote>
<p>The mutant phenotypes are still observed at 22 °C.</p>
<disp-quote content-type="editor-comment">
<p>If so, will it be possible to get a complete rescue of the slT2A mutant phenotypes with the hPLCG1 cDNA at 22{degree sign}C? This dataset is essential to establish Drosophila as an ideal model to study the PLCG1 de novo variants.</p>
</disp-quote>
<p>Thank you for the suggestion. It is difficult to directly assess the rescue ability of the PLCG1 cDNAs due to the toxicity. However, our ectopic expression assays show that the variants are more toxic than the reference with variable severities, suggesting that the variants are deleterious.</p>
<p>The ectopic expression strategy has been used to evaluate the consequence of genetic variants and has significantly contributed to the interpretation of their pathogenicity in many cases (reviewed in Her et al., Genome, 2024, PMID: 38412472).</p>
<disp-quote content-type="editor-comment">
<p>(5) Localisation and western blot assays to check if the introduction of the de novo mutations can have an impact on the sub-cellular targeting of the protein or protein stability respectively.</p>
</disp-quote>
<p>Thank you for the suggestion.</p>
<p>We expressed PLCG1 cDNAs in the larval salivary glands and performed antibody staining (rabbit anti-Human PLCG1; 1:100, Cell Signaling Technology, #5690). The larval salivary gland are composed of large columnar epithelia cells that are ideal for analyzing subcellular localization of proteins. The PLCG1 proteins are cytoplasmic and localize near the cell surface, with some enrichment in the plasma membrane region. The variant proteins are detected, and did not show significant difference in expression level or subcellular distribution compared to the reference. We did not include this data.</p>
<disp-quote content-type="editor-comment">
<p>(6) Analysing the nature of the reported gain of function (experimental proof for the same is missing in the manuscript) variants:</p>
<p>Instead of directly showing the effect of introducing the de novo variant transgenes in the Drosophila model especially when the full-length PLCG1 is not able to completely rescue the slT2A phenotype;</p>
<p>(i) Show that the gain-of-function variants can have an impact on the protein function or signalling via one of the three signalling outputs in the mammalian cell culture system: (i) inositol-1,4,5-trisphosphate production, (ii) intracellular Ca2+ release or (iii) increased phosphorylation of extracellular signal-related kinase, p65, and p38.</p>
</disp-quote>
<p>We appreciate the reviewer’s suggestion. We utilized the CaLexA (calcium-dependent nuclear import of LexA) system (Masuyama et al., J Neurogenet, 2012, PMID: 22236090) to assess the intracellular Ca<sup>2+</sup> change associated with the expression of PLCG1 cDNAs in fly wing discs. The results show that, compared to the reference, expression of the D1019G or D1165G variants leads to elevated intracellular Ca<sup>2+</sup> levels, similar to the hyperactive S1021F and D1165H variants. However, the H380R or L597F variants did not show a detectable phenotype in this assay. These results suggest that D1019G and D1165G are hyperactive variants, whereas H380R and L597F variant are not, or their effect is too mild to be detected in this assay. We have updated the related sections in the manuscript and Figures 5A and S5.</p>
<disp-quote content-type="editor-comment">
<p>OR</p>
<p>(ii) Run a molecular simulation to demonstrate how the protein's auto-inhibited state can be disrupted and basal lipase activity increased by introducing D1019G and D1165G, which destabilise the association between the C2 and cSH2 domains. The H380R variant may also exhibit characteristics similar to the previously documented H335A mutation which leaves the protein catalytically inactive as the residue is important to coordinate the incoming water molecule required for PIP2 hydrolysis.</p>
</disp-quote>
<p>We utilized the DDMut platform, which predicts changes in the Gibbs Free Energy (ΔΔG) upon single and multiple point mutations (Zhou et al., Nucleic Acid Res, 2023, PMID: 37283042), to gain insight into the molecular dynamics changes of variants. The results are now presented in Figure S7.</p>
<p>Additionally, we performed Molecular dynamics (MD) simulations. The results show that, similar to the hyperactive D1165H variant, the D1019G and D11656G variants exhibit increased disorganization, with a higher root mean square deviations (RMSD) compared to the reference PLCG1.The data are also presented in the updated Figure S7.</p>
<disp-quote content-type="editor-comment">
<p>(7) Clarify the reason for carrying out the wing-specific and eye-specific experiments using nub-gal4 and eyless-gal4 at 29˚C despite the high gal4 toxicity at this temperature.</p>
</disp-quote>
<p>We used high temperature and high expression level to see if the mild H380R and L597F variants could show phenotypes in this condition.</p>
<p>The toxicity of the two strong variants (D1019G and D1165G) has been consistently confirmed in multiple assays at different temperatures.</p>
<disp-quote content-type="editor-comment">
<p>(8) For the sake of completeness the authors should also report other variants identified in the genomes of these patients that could also contribute to the clinical features.</p>
</disp-quote>
<p>Thank you!</p>
<p>The additional variants and their potential contributions to the clinical features are listed and discussed in Table 1 and its legend.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p>
<p>The manuscript's significant contribution is tempered by a lack of comprehensive analysis using the generated genetic reagents in Drosophila. To enhance our understanding of the PLCG1 orthologs, I suggest the following:</p>
<p>(1) A more detailed molecular analysis to distinguish the actions of sl variants from the wild-type could be very informative. For example, utilizing the HA-epitope tag within the current UAS-transgenes could reveal more about the cellular dynamics and abundance of these variants, potentially elucidating mechanisms beyond gain-of-function.</p>
</disp-quote>
<p>We appreciate the reviewer’s suggestion. The UAS-sl cDNA constructs contain stop codon and do not express an HA-epitope tag. Alternatively, we utilized commercially available antibodies against human PLCG1 antibodies to assess the subcellular localization and protein stability by expressing the reference and variant PLCG1 cDNAs in Drosophila larval salivary glands. The reference proteins are cytoplasmic with some enrichment along the plasma membrane. However, we did not observe significant differences between the reference and variant proteins in this assay. We did not include this data.</p>
<disp-quote content-type="editor-comment">
<p>(2) I suggest further investigating the relative contributions of developmental processes and acute (Adult) effects on the sl-variant phenotypes observed. For example, employing systems that allow for precise temporal control of gene expression, such as the temperature-sensitive Gal80, could differentiate between these effects, shedding light on the mechanisms that affect longevity and locomotion. This knowledge would be vital for a deeper understanding of the corresponding human disorders and for developing therapeutic interventions.</p>
</disp-quote>
<p>We appreciate the reviewer’s suggestion. We utilized <italic>Tub-GAL4, Tub-GAL80<sup>ts</sup></italic> to drive the expression of sl wild-type or variant cDNAs, and performed temperature shifts after eclosion to induce expression of the cDNAs only in adult flies. The <italic>sl<sup>D1184G</sup></italic> variant (corresponding to <italic>PLCG1<sup>D1165G</sup></italic>) caused severely reduced lifespan and the flies mostly die within 10 days. The <italic>sl<sup>D1041G</sup></italic> variant (corresponding to <italic>PLCG1<sup>D1019G</sup></italic>) led to reduced longevity and locomotion. The <italic>sl<sup>H384R</sup></italic> variant (corresponding to <italic>PLCG1<sup>H380R</sup></italic>) showed only a mild effect on longevity and no significant effect on climbing ability. These results suggest that the two strong variants (<italic>sl<sup>D1041G<sup/></sup></italic> and <italic>sl<sup>D1184G</sup></italic>) contribute to both developmental and acute effects while the H384R variant mainly contributes to developmental stages.</p>
<p>I also suggest a more refined analysis of overexpression toxicity. Rather than solely focusing on ubiquitous transgene expression, overexpressing transgene in endogenous pattern using sl-t2a-Gal4 may yield a more nuanced understanding of the pathogenic mechanisms of gain-of-function mutations, particularly in the pathogenesis associated with these variants exclusively located in the coding regions.</p>
<p>We appreciate the reviewer’s suggestion. We therefore performed the experiments using <italic>sl<sup>T2A</sup></italic> to drive overexpression of<italic>PLCG1</italic>cDNAs in heterozygous female progeny with one copy of wild-type <italic>sl+ (sl<sup>T2A</sup>/ yw &gt; UAS-cDNAs)</italic>. In this context, expression of <italic>PLCG1<sup>Reference<sup/></sup></italic>, <italic>PLCG1<sup>H380R</sup></italic>or<italic>PLCG1<sup>L597F</sup></italic> is viable whereas expression of <italic>PLCG1<sup>D1019G</sup></italic> or <italic>PLCG1<sup>D1165G</sup></italic> is lethal, suggesting that the <italic>PLCG1<sup>D1019G</sup></italic> and <italic>PLCG1<sup>D1165G</sup></italic> variants exert a strong dominant toxic effect while the <italic>PLCG1<sup>H380R</sup></italic>and <italic>PLCG1<sup>L597F<sup/></sup></italic> are comparatively milder. Similar patterns have been consistently observed in other ectopic expression assays with varying degrees of severity. These results are updated in the manuscript and figures.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p>
<p>The work in the paper could be usefully extended by determining the effects of expressing His380Phe and His380Ala in flies. These variants suppress PLCG1 activity, so their phenotype, if any, would be predicted not to be the same as His380Arg. Determining this would add further strength to the conclusions of the paper.</p>
</disp-quote>
<p>We thank the reviewer for the constructive suggestions! We have tested the enzymatic-dead H380A variant, which still exhibits toxicity when expressed in <italic>sl<sup>T2A</sup>/Y</italic> hemizygous flies, but it is not toxic in heterozygous females suggesting that the reduced eclosion rate is likely not directly associated with enzymatic activity. We have updated the manuscript and figures accordingly.</p>
</body>
</sub-article>
</article>